| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
InspireMD Inc.$0.72
+0.03 (+3.92%)
F 10Pipeline Score MedTech · Commercial
Market Cap
46.84 M
EPS
-0.74
P/E Ratio
-
Value Trade
29.19 K
SEC Financials
Q1 2026Dilution Risk
Revenue
3.40 M
R&D Expenses
4.76 M
Operating CF
-12.34 M
Total Assets
56.47 M
Total Liabilities
12.85 M
Equity
43.62 M
D/E Ratio
12,345
-11.5 %
Week
-25.37 %
1 Month
-45.36 %
3 Month
-43.82 %
6 Month
-80.47 %
5 Year
-100 %
All Time
Cash Data
Cash Position
41.57 M
Monthly Burn
4.11 M
Runway
8.2 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
159.32 K
52 Week Range
0.97 - 2.93
% held by Insiders
28.65 %
% held by Institutions
42.9 %
Enterprise Value
8.38 M
Total Shares
46.88 M
Short %
0.22 %
Float Shares
33.61 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F10
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 8%
Micro Cap (rank 839 of 911)
Percentile RankInspireMD Inc. has significant pipeline risk (10/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
CGuard Prime 80 cm | prevention of stroke | — | 2026-06-11 | 100% acute device success rate; no deaths; no strokes; no myocardial infarctions; no stent thrombosis; complete stent patency observed at 30 days Read More | InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures Read More | |
CGuard Prime 80 cm | prevention of stroke | — | 2026-06-11 | 100% acute device success rate; no deaths; no strokes; no myocardial infarctions; no stent thrombosis; complete stent patency observed at 30 days Read More | InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures Read More | |
CGuard Prime 80 cm | prevention of stroke | — | 2026-06-11 | 100% acute device success rate; no deaths; no strokes; no myocardial infarctions; no stent thrombosis; complete stent patency observed at 30 days Read More | InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in NSPR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
NSPR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
NSPRInspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
InspireMD, Inc. has announced the approval of inducement grants totaling 91,161 shares of restricted stock to six new non-executive employees, effective June 12, 2026, under Nasdaq Listing Rule 5635(c)(4). This initiative aims to attract talent as the company continues to develop its CGuard Prime carotid stent system. The stock will vest over a three-year period contingent upon continued employment. Despite this positive development, the company is facing serious risks due to a recent product recall and concerns over its financial stability.
Read more →NSPR▼ -5.9%on this newsshared move
InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures
InspireMD announced positive 30-day outcomes from the CGUARDIANS II clinical trial for its CGuard Prime 80 cm carotid stent used in TCAR procedures. The trial reported a 100% acute device success rate, with no deaths or major adverse events. The company anticipates potential FDA approval in the latter half of the year, aiming to enhance its presence in the TCAR market.
Read more →NSPR▼ -7.2%on this newsshared move
InspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR Procedures
InspireMD has announced the enrollment of the first patient in the CGUARDIANS III pivotal study for its SwitchGuard neuro protection system, intended for use in transcarotid artery revascularization procedures. This study aims to evaluate the safety and efficacy of the SwitchGuard NPS in providing cerebral embolic protection. The initiative is seen as a significant advancement in the company's efforts to improve patient safety and stroke prevention.
Read more →NSPRInspireMD to Participate in Upcoming Bank of America Securities 2026 Global Healthcare Conference
InspireMD, Inc. announced its participation in the Bank of America Securities 2026 Global Healthcare Conference scheduled for May 13th. The company will present its CGuard®Prime carotid stent system, aimed at preventing strokes. A live audio webcast will be available for investors, enhancing transparency and engagement.
Read more →NSPRInspireMD Announces FDA Approval of Investigational Device Exemption Application for CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System
InspireMD, Inc. has received FDA approval for its Investigational Device Exemption application to begin the CGUARDIANS III pivotal study of the SwitchGuard neuro protection system. This study will utilize enhancements from a previous IDE approval and is aimed at improving outcomes in transcarotid artery revascularization procedures. The company anticipates a commercial launch in 2027, contingent on further approvals.
Read more →NSPRInspireMD Initiates Voluntary U.S. Recall of CGuard® Prime 135 cm Carotid Stent Delivery System
InspireMD has voluntarily recalled its CGuard® Prime 135 cm carotid stent delivery system after performance issues were identified during a controlled launch. This decision does not affect the safety of previously implanted CGuard stents, which continue to demonstrate strong clinical outcomes. The company anticipates FDA approval for its original delivery system in Q3 2026 and is implementing design improvements for the recalled product.
Read more →NSPRInspireMD Reports First Quarter 2026 Financial Results - Reports total Q1 2026 revenue of $3.4 million, representing year-over-year growth of 122% - - Received IDE approval from FDA to initiate the CGUARDIANS III clinica
InspireMD reported its financial results for the first quarter of 2026, highlighting a revenue of $3.4 million, which marks a 122% increase compared to the same period last year. The company received FDA approval to initiate the CGUARDIANS III clinical trial for its SwitchGuard neuro protection system. Despite the positive revenue growth, InspireMD is facing challenges due to a voluntary pause in the commercialization of its CGuard Prime 135 cm system in the U.S. and anticipates financial implications from a recall of the device. Nevertheless, the company is optimistic about upcoming FDA approvals that could enhance market opportunities.
Read more →NSPRInspireMD Initiates Voluntary U.S. Recall of CGuard Prime 135 cm Carotid Stent Delivery System - Strong clinical demand continues in Q1 2026 with global year-over-year unit sales growth of 53% and quarter-over-quarter U.
InspireMD has announced a voluntary recall of its CGuard Prime 135 cm carotid stent delivery system in consultation with the FDA due to performance issues during its controlled launch. Despite this setback, the company continues to experience significant global demand, reporting a 53% increase in year-over-year sales. InspireMD plans to enhance the delivery system's technical performance and anticipates receiving FDA approval for its original delivery system in Q3 2026. The recall affects U.S. commercialization, leading to the withdrawal of full-year revenue guidance.
Read more →NSPR▼ -5.8%on this newsshared move
InspireMD to Announce First Quarter 2026 Financial Results
InspireMD, Inc. plans to release its first quarter financial results on May 4, 2026. The announcement will be accompanied by a conference call at 4:30 p.m. Eastern Time to discuss the results and recent highlights. Interested participants can register online for the call and access the webcast.
Read more →NSPRInspireMD to Participate in Upcoming 25th Annual Needham Virtual Healthcare Conference
InspireMD, Inc. (Nasdaq: NSPR) will present at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026. The event will feature a live audio webcast available on the company's investor page. InspireMD aims to set a standard in carotid stenting with its CGuard®Prime system, enhancing stroke prevention.
Read more →NSPRInspireMD Reports Fourth Quarter and Full Year 2025 Financial Results - Miami, FL
InspireMD, Inc. reported its fourth quarter and full year 2025 financial results, highlighting a revenue increase of 62% in Q4 compared to the same period the previous year. The company has achieved strong commercial traction in the U.S. with its CGuard Prime stent and completed enrollment in the CGUARDIANS II pivotal trial. Despite the revenue growth, InspireMD reported a higher net loss of $11.8 million for Q4 2025, necessitating increased operating expenses as the company invests in resources to support its market growth. Looking ahead, InspireMD anticipates revenue growth of 45% to 65% for 2026, estimating revenues between $13 million and $15 million.
Read more →NSPRInspireMD to Announce Fourth Quarter and Full Year 2025 Financial Results
InspireMD, Inc. will release its fourth quarter and full year 2025 financial results on March 18, 2026. The company will host a conference call at 8:30 a.m. ET to discuss these results and recent highlights. The event reflects InspireMD's commitment to investor communication and transparency.
Read more →NSPRInspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 20, 2026
InspireMD, Inc. announced the approval of inducement grants totaling 36,118 shares of restricted stock to a new non-executive employee. This decision, made by the Compensation Committee, aims to attract talent under Nasdaq Listing Rule 5635(c)(4). The restricted stock will vest over three years, contingent on continued employment.
Read more →NSPR▼ -5.8%on this news
InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC)
InspireMD, Inc. announced the publication of its C-GUARDIANS pivotal trial results in the Journal of the American College of Cardiology. The CGuard® Prime carotid stent system showcased record low rates of major adverse events, including a 30-day disabling stroke or myocardial infarction rate of 0.95% and a one-year ipsilateral stroke rate of 1.93%. These outcomes were achieved even in a patient cohort with a significant percentage of symptomatic cases. The publication is expected to enhance physician awareness and drive the adoption of this technology in carotid artery stenosis treatment.
Read more →NSPRLandmark CREST-2 Study Published in the New England Journal of Medicine Highlights the Benefits of Carotid Artery Stenting
The CREST-2 study published in the New England Journal of Medicine highlights the effectiveness of carotid artery stenting (CAS) for patients with asymptomatic carotid stenosis. The study found that stenting significantly reduced the risk of stroke or death compared to intensive medical management alone. InspireMD's CGuard technology was noted for its low adverse event rates, reinforcing the role of CAS in treatment protocols.
Read more →NSPR▼ -11.5%on this newsshared move
InspireMD to Participate in Upcoming Piper Sandler 37th Annual Healthcare Conference
InspireMD, Inc. will take part in the Piper Sandler 37th Annual Healthcare Conference on December 3rd. The company will engage in a fireside discussion at 12:30 pm ET, which will be accessible via a live audio webcast. InspireMD is known for its CGuard®Prime carotid stent system aimed at preventing strokes.
Read more →NSPR▼ -7.2%on this news· ran to -21% by day 3
InspireMD Reports Third Quarter 2025 Financial Results
InspireMD, Inc. reported a 39% revenue increase for Q3 2025, reaching $2.5 million. The U.S. commercial launch of the CGuard Prime carotid stent system contributed significantly to this growth. Despite the positive revenue trends, the company experienced a net loss of $12.7 million, reflecting higher operating expenses associated with expansion efforts.
Read more →NSPRInspireMD Names Peter A. Soukas, M.D., as Chief Medical Officer
InspireMD has appointed Dr. Peter A. Soukas as Chief Medical Officer to enhance its clinical and medical strategies. Dr. Soukas, an expert in vascular intervention, will oversee the launch of the CGuard Prime carotid stent in the U.S. market. His extensive experience and commitment to improving patient outcomes are expected to significantly benefit the company during this pivotal time.
Read more →NSPRInspireMD to Announce Third Quarter 2025 Financial Results
InspireMD, Inc. (NSPR), a developer of stroke prevention technologies, is set to announce its third quarter 2025 financial results on November 4, 2025. The announcement will be accompanied by a conference call and webcast at 8:30 a.m. Eastern Time. This event highlights the company's ongoing commitment to communication with investors and the importance of its financial performance.
Read more →NSPRInspireMD Announces the Appointment of Dan Dearen to its Board of Directors
InspireMD has appointed Dan Dearen to its Board of Directors, bringing nearly 40 years of experience in the medical device sector. His expertise is expected to support InspireMD's strategic goals, particularly in the U.S. launch of the CGuard Prime carotid stent system. The company aims to change vascular medicine standards with this product.
Read more →NSPRInspireMD to Present at Upcoming H.C. Wainwright 27th Annual Global Investment Conference
InspireMD, Inc. will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10th. The company focuses on its CGuard® Prime carotid stent system, which is designed to prevent strokes. A live audio webcast of the presentation will be available on their website.
Read more →NSPR▼ -8.2%on this news
InspireMD Reports Second Quarter 2025 Financial Results --- Management to host investor conference call today, August 5 th , at 8:30am ET --- Miami, FL
InspireMD, Inc. reported its financial results for the second quarter of 2025, notably announcing the FDA approval of its CGuard Prime carotid stent system and its U.S. commercial launch. While revenue showed slight growth, operating expenses surged, leading to a wider net loss compared to the same period last year. The company raised $58 million to support its growth initiatives and strengthened its leadership team with a new CFO. The European launch is anticipated in the third quarter, reflecting the company's strategic expansion plans.
Read more →NSPR▲ +17.7%on this newsshared move
InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors
InspireMD has appointed Raymond W. Cohen to its Board of Directors. Cohen brings over 40 years of experience in medical technology, having successfully led companies like Axonics, Inc. and Vessix Vascular, Inc. His expertise is expected to enhance InspireMD's strategic vision and execution, particularly following the recent approval of the CGuard Prime carotid stent system.
Read more →NSPR▲ +17.7%on this newsshared move
InspireMD Announces Combined Financings of $58 Million
InspireMD has successfully raised approximately $58 million through a PIPE financing and warrant exercises, driven by the FDA's PMA approval of its CGuard Prime carotid stent system. The funding aims to support the company's growth as it launches the product in the U.S. market. CEO Marvin Slosman emphasized the importance of this capital in expanding commercial operations and enhancing the company's financial stability.
Read more →NSPRInspireMD to Announce Second Quarter 2025 Financial Results
InspireMD, Inc. (Nasdaq: NSPR) will release its second quarter 2025 financial results on August 5, 2025. The company will host a conference call and webcast at 8:30 a.m. ET to discuss these results and recent highlights. The call and the subsequent replay will be accessible from InspireMD's website, providing a platform for investor engagement.
Read more →NSPR▲ +7.5%on this news
InspireMD Announces U.S. Commercial Launch of CGuard Prime Carotid Stent System for the Prevention of Stroke Miami, Florida
InspireMD, Inc. has announced the U.S. commercial launch of its CGuard Prime carotid stent system aimed at preventing strokes. This device received approval from the U.S. Food and Drug Administration and is designed to minimize embolism risk while ensuring optimal blood flow. With unique features such as a dual-layer structure and advanced MicroNet technology, the stent is expected to enhance patient safety. The launch marks a significant milestone in the company's growth trajectory, as it continues to gain market share in over 30 countries.
Read more →NSPRInspireMD Announces FDA Approval for CGuard Prime Carotid Stent System for the Prevention of Stroke Miami, Florida
InspireMD has announced the FDA's approval of its CGuard Prime Carotid Stent System for stroke prevention. This groundbreaking device demonstrates exceptional safety and efficacy, having recorded the lowest rates of major adverse events in any pivotal trial for carotid interventions. The approval follows the positive results from the C-GUARDIANS trial, which included 316 patients. With over 65,000 implants sold globally, InspireMD is positioned to launch the product commercially in the U.S., backed by substantial financing and ongoing development efforts.
Read more →NSPR▼ -7.2%on this news
InspireMD Announces CE Mark Approval for CGuard Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke Miami, Florida
InspireMD, Inc. has announced the receipt of CE Mark approval for its CGuard Prime Embolic Prevention System (EPS) under the European Medical Device Regulation (MDR). This regulatory milestone is key for the commercial launch of CGuard Prime in European markets and supports the company's strategy for expansion, including a potential U.S. launch later this year, contingent on FDA approval. The CGuard technology is designed to provide enhanced safety by reducing embolic events in patients requiring carotid artery interventions. InspireMD aims to establish its products as the industry standard for carotid stenting, leveraging proprietary technology for better patient outcomes.
Read more →NSPRInspireMD Announces Appointment of Michael Lawless as Chief Financial Officer Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Miami, Florida
InspireMD, Inc. has announced the appointment of Michael Lawless as its Chief Financial Officer, effective by June 30, 2025. Lawless, who has significant financial leadership experience in the healthcare sector, will succeed Craig Shore, who has held the position for nearly 15 years. Alongside his appointment, InspireMD plans to grant Lawless restricted stock and stock options as part of his inducement during a critical phase for the company, particularly with the upcoming launch of its CGuard Prime carotid stent system in the U.S. market.
Read more →NSPRInspireMD Reports First Quarter 2025 Financial Results - Management to host investor conference call today, May 9 th , at 8:30am ET - Miami, FL
InspireMD, Inc. has reported its financial results for the first quarter of 2025, showing a slight increase in revenue attributed to continued adoption of its CGuard technology. However, the company also faced significant increases in operating expenses and a larger net loss compared to the same period last year. Management remains optimistic about an anticipated FDA approval for the CGuard Prime device in the third quarter of 2025. They highlighted the successful development of their commercial team in preparation for this potential approval. A conference call is scheduled for today to discuss these developments further.
Read more →NSPRInspireMD to Present at Upcoming Bank of America 2025 Healthcare Conference
InspireMD, Inc. will present at the Bank of America 2025 Healthcare Conference on May 14, 2025. The management team will discuss their CGuard™ Prime carotid stent system, aimed at treating carotid artery disease and stroke prevention. A live audio webcast of the presentation will be available on their website for 90 days post-event. This opportunity highlights InspireMD's focus on advancing their proprietary MicroNet® technology in the carotid stenting market.
Read more →NSPRInspireMD to Announce First Quarter 2025 Financial Results
InspireMD, Inc. announced that it will release its first quarter 2025 financial results on May 9, 2025. Alongside this announcement, the company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial performance and recent developments. This event aims to provide stakeholders with relevant updates and insights into the company's future direction.
Read more →NSPRInspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference
InspireMD, Inc. (Nasdaq: NSPR) has announced its upcoming presentation at the 24th Annual Needham Virtual Healthcare Conference scheduled for April 9, 2025. The presentation will showcase the company's CGuard™ Prime carotid stent system aimed at treating carotid artery disease and preventing stroke. A live audio webcast of the event will be available for 90 days on InspireMD's website. The company emphasizes its focus on using proprietary technology to enhance patient outcomes.
Read more →NSPRInspireMD Reports Fourth Quarter and Full Year 2024 Financial Results - Management to host investor conference call today, March 12 th , at 8:30am ET - Miami, FL
InspireMD, Inc. reported its financial results for the fourth quarter and full year of 2024, showing both growth in revenue but also higher operating costs. The company engaged with the FDA for the PMA application for its CGuard Prime carotid stent system, which is crucial for their anticipated U.S. commercial launch. While revenues increased, the net loss widened compared to the previous year, raising concerns about ongoing financial stability. CEO Slosman expressed optimism about upcoming clinical and regulatory milestones, particularly regarding the product launch planned for the first half of 2025.
Read more →NSPRInspireMD to Announce Fourth Quarter and Full Year 2024 Financial Results
InspireMD, Inc. (Nasdaq: NSPR) will announce its fourth quarter and full year 2024 financial results on March 12, 2025. The announcement will be accompanied by a conference call to discuss financial highlights and results. InspireMD focuses on utilizing its proprietary MicroNet® technology to enhance outcomes in carotid artery disease treatment.
Read more →NSPRInspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime™ 80 cm Carotid Stent System for Use in TCAR procedures
InspireMD and NAMSA announced their partnership to conduct the CGUARDIANS II pivotal study, focusing on the CGuard Prime 80 cm carotid stent system for use in TCAR procedures. This study aims to evaluate the device's safety and effectiveness, with an enrollment target of at least 50 evaluable patients. The partnership leverages NAMSA's clinical and regulatory expertise to streamline the study process. InspireMD emphasizes that TCAR represents a growing market with over 30,000 procedures performed annually in the U.S.
Read more →NSPRInspireMD Announces Expected Retirement of its CFO Craig Shore and CFO Transition in 2025 Miami, Florida
InspireMD, Inc. (Nasdaq: NSPR) has announced the expected retirement of its Chief Financial Officer, Craig Shore, who will stay until a successor is appointed. Shore has been with the company for 15 years and played a key role in its development as a leader in carotid interventions. The firm is pursuing potential FDA approval for its stent system in mid-2025, and Shore's departure comes at a time when the company seeks to enhance its focus on investment and market presence. InspireMD has initiated a search to find a new CFO amidst ongoing planning for future growth.
Read more →NSPRInspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR) Study represents a significant step forwar
InspireMD has announced the enrollment of the first patient in its CGUARDIANS II clinical trial, which evaluates the CGuard Prime Carotid Stent System for transcarotid artery revascularization procedures. This pivotal study signifies an important milestone for the company as it approaches potential FDA approval. The trial, led by principal investigator Dr. Patrick Muck, aims to recruit a minimum of 50 evaluable patients and will assess the device's acute and technical success. InspireMD is optimistic about the CGuard Prime's performance based on prior clinical results and aims to address the growing market for carotid procedures.
Read more →NSPR▲ +10.9%on this news
InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors Miami, Florida
InspireMD, Inc. has announced the appointment of Scott R. Ward to its Board of Directors, enhancing its leadership team with his extensive experience in the medical technology sector. Ward previously served as CEO of Cardiovascular Systems, Inc., acquired by Abbott, and is expected to significantly contribute to InspireMD's strategic direction, particularly as the company nears U.S. approval for its CGuard Prime stent system. This appointment aligns with InspireMD's goals to innovate in carotid stenting and stroke prevention, potentially shifting the market standard.
Read more →NSPRInspireMD Reports Third Quarter 2024 Financial Results and Provides Business Update - Submitted a Premarket Approval (PMA) application to the FDA seeking marketing approval of the CGuard Prime carotid stent system in the
InspireMD reported its financial results for Q3 2024, revealing a revenue increase of 16.3% to $1.81 million while establishing its headquarters in Miami to bolster future product launches. The company has submitted a PMA application to the FDA for the CGuard Prime carotid stent system and received IDE approval for a pivotal study. Despite the positive advancements, the company also reported a rise in operating expenses and a net loss of $7.89 million. InspireMD remains focused on addressing carotid artery disease with innovative solutions.
Read more →NSPRInspireMD to Report Third Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, November 12th
InspireMD, Inc. (Nasdaq: NSPR) announced that it will report its third quarter 2024 financial results on November 12, 2024. A conference call and webcast will take place at 8:30 a.m. EDT on the same day to discuss the financial outcomes and provide updates on corporate developments. The company emphasizes its commitment to improving carotid stenting outcomes using its proprietary MicroNet technology.
Read more →NSPR▼ -5.7%on this news
InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System Miami, Florida
InspireMD, Inc. has announced the establishment of its global headquarters in Miami, Florida, aimed at supporting the anticipated U.S. launch of its CGuard Prime carotid stent system in early 2025, pending FDA approval. The new facility is expected to enhance operational capabilities and build a strong commercial team in the U.S. market. CEO and other executives highlighted the move as crucial for driving long-term growth and satisfying the demand for their innovative medical technologies. The company has also submitted a PMA application to the FDA for the CGuard Prime system as part of its readiness for market introduction.
Read more →NSPRInspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System Miami, Florida
InspireMD, Inc. recently received FDA approval for its Investigational Device Exemption (IDE) to initiate the CGUARDIANS II pivotal study for the CGuard Prime 80cm Carotid Stent System. This study aims to facilitate the approval process for transcarotid revascularization (TCAR) procedures. Lead investigators from notable institutions have been appointed, enhancing the trial's credibility. The company aims to position CGuard Prime as a market leader in managing carotid diseases and preventing strokes, despite facing potential financial and regulatory challenges down the line.
Read more →NSPRInspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard Prime Carotid Stent System PMA based on overwhelmingly positive results from the pivotal C-GUARDIANS
InspireMD, Inc. has submitted a Premarket Approval (PMA) application to the FDA for its CGuard Prime carotid stent system, based on positive results from the C-GUARDIANS clinical trial. The trial demonstrated a major adverse event rate of just 1.95% over twelve months, marking it as a significant event in carotid stenting. Should the PMA be approved, a commercial launch is projected for the first half of 2025. The submission represents a crucial step forward in the company's strategy to penetrate the U.S. market for stroke prevention devices.
Read more →NSPRInspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update - Announced positive outcomes from the C-GUARDIANS IDE clinical trial of the CGuard Prime carotid stent system demonstrating a one-year
InspireMD, Inc. reported its second quarter 2024 financial results, highlighting a significant milestone with the C-GUARDIANS IDE trial showing the lowest one-year primary endpoint event rate for carotid stents. The company plans to submit a Premarket Approval application to the FDA this quarter and raised $17.9 million from Series H warrant exercises. However, the financial report also displays increased operational costs and a higher net loss compared to the previous year, indicating ongoing challenges despite progress in clinical trials and potential regulatory advancements.
Read more →NSPRInspireMD Congratulates CREST-2 Investigators on Completion of Trial Enrollment
InspireMD, Inc. announced the successful completion of enrollment in the CREST-2 clinical trials, where its CGuard carotid stent was utilized. The trials focus on evaluating carotid revascularization methods for patients with high-grade carotid stenosis who do not exhibit stroke symptoms. Lead investigators acknowledged the trial's significance in advancing treatment options for these patients. InspireMD's device was notable for being the only second-generation investigational option approved by the FDA for inclusion in the study.
Read more →NSPR▼ -16.9%on this news
InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6th
InspireMD, Inc. (Nasdaq: NSPR) has announced that it will report its financial results for the second quarter of 2024 on August 6th, prior to market opening. The company will hold a conference call at 8:30 a.m. EDT the same day to discuss the financial results and provide updates on corporate activities. InspireMD is focused on utilizing its MicroNet® technology to improve outcomes in carotid artery disease treatments.
Read more →NSPRInspireMD Announces Full Exercise of Series H Warrant Tranche for Gross Proceeds of $17.9 Million Series H warrants exercisable following release of positive outcomes results related to one-year follow-up from the Compan
InspireMD, Inc. has announced the complete exercise of 12.9 million Series H warrants, generating gross proceeds of $17.9 million. This exercise occurred following the release of positive results from the one-year follow-up of the company's C-GUARDIANS pivotal trial. The raised capital will help advance InspireMD's CGuard Prime Carotid Stent System towards potential FDA approval and enhance its growth strategy. The firm expressed gratitude for the continued support from its investors, indicating confidence in further milestones and commercialization efforts.
Read more →NSPRInspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024 Data demonstrate lowest reported primary endp
InspireMD announced positive results from the one-year follow-up of its C-GUARDIANS IDE clinical trial of the CGuard Carotid Stent System. The trial demonstrated an exceptionally low primary endpoint event rate of 1.95%, reinforcing its potential in preventing stroke and other major adverse events in patients with carotid artery stenosis. The data will support a Premarket Approval application to the FDA expected in the second half of 2024, with a commercial launch planned for the first half of 2025 if approved. The trial reflects a comprehensive engagement with 316 patients across 24 sites in the U.S. and Europe.
Read more →NSPRInspireMD Reports First Quarter 2024 Financial Results and Provides Business Update - Generated first quarter 2024 CGuard EPS revenue of $1.51 million, an increase of 22.0% over the first quarter of 2023 - - Announced th
InspireMD, Inc. reported financial results for the first quarter of 2024, showcasing a revenue growth of 22.0% to $1.51 million compared to the same period in 2023. The company sold 2,553 CGuard EPS stent systems, marking a 25.6% increase year-over-year. An abstract detailing one-year outcomes from the C-GUARDIANS IDE clinical trial has been accepted for a presentation at LINC 2024, indicating ongoing clinical advancements. However, despite the revenue growth, InspireMD reported a net loss of $7,032,000 due to rising operational costs.
Read more →NSPRInspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th
InspireMD, Inc. (Nasdaq: NSPR) announced that it will report its first quarter 2024 financial results on May 14, 2024, prior to the market opening. A conference call and webcast will follow at 8:30 am EDT to discuss these results and provide updates on corporate developments. The company focuses on its CGuard™ Embolic Prevention Stent System for the treatment of carotid artery disease.
Read more →NSPRInspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference
InspireMD, Inc. (Nasdaq: NSPR) will present an update at the 23rd Annual Needham Virtual Healthcare Conference from April 8-11, 2024. The presentation, led by CEO Marvin Slosman, is scheduled for April 10 from 8:00 AM to 8:40 AM ET. InspireMD develops the CGuard™ Embolic Prevention Stent System aimed at preventing strokes and achieving long-term positive outcomes.
Read more →NSPRInspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024 Tel Aviv, Israel, and Miami, Florida
InspireMD, Inc. has announced that an abstract detailing one-year follow-up results from its C-GUARDIANS IDE clinical trial has been accepted for presentation at the upcoming LINC 2024 conference. The trial evaluated the CGuard Carotid Stent System for carotid artery stenosis treatment. Following positive initial outcomes presented at previous conferences, the company expresses optimism that the longer-term results will further demonstrate the device's efficacy and safety, potentially facilitating a Premarket Approval Application in the near future.
Read more →NSPRInspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update - Record fourth quarter 2023 CGuard EPS revenue of $1.76 million increased 71.6% over fourth quarter 2022 - - Announced p
InspireMD reported strong financial results for Q4 2023, achieving a record revenue of $1.76 million, which represents a 71.6% increase compared to the same period in 2022. The company also announced positive 30-day data from its C-GUARDIANS clinical trial and new leadership appointments for its upcoming studies. Despite the revenue growth, InspireMD recorded a net loss of $19.9 million for the year, highlighting ongoing financial challenges. The increase in operating expenses and the need for future capital raising could pose risks to the company's objectives.
Read more →NSPRInspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th
InspireMD, Inc. (Nasdaq: NSPR) announced it will report its fourth quarter and full-year 2023 financial results on March 6th, 2024, prior to the market opening. The company will host a conference call and webcast at 8:30 am EST to discuss these results and provide updates on corporate developments. InspireMD specializes in the CGuard™ Embolic Prevention Stent System for carotid artery disease treatment and stroke prevention.
Read more →NSPRInspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System
InspireMD, Inc. has appointed recognized vascular surgeons as principal investigators for its C-GUARDIANS II clinical trial of the SwitchGuard Neuroprotection System. The trial aims to enhance patient safety during carotid revascularization procedures. CEO Marvin Slosman highlighted this as a major milestone, with the goal of establishing the SwitchGuard system as a leading option in carotid interventions. However, the company also faces various financial and operational challenges moving forward.
Read more →NSPRInspireMD Receives CE Mark Recertification Under EU's New Medical Device Regulation (MDR) Regulatory Framework Tel Aviv, Israel, and Miami, FL
InspireMD, Inc. announced the receipt of CE Mark recertification under the European Union's new Medical Device Regulation (MDR), allowing it to continue marketing its CGuard Embolic Prevention Carotid Stent System. CEO Slosman highlighted the challenges faced during the regulatory transition but expressed optimism about the future. The company is also making progress on its C-GUARDIANS U.S. IDE trial, with primary endpoint results expected in mid-2024 and plans for a PMA application submission later this year.
Read more →NSPRInspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America
InspireMD has appointed Pete Ligotti as Executive Vice President and General Manager of North America, bringing over 30 years of experience in medical technology. This move comes as the company scales its U.S. operations in preparation for potential approval of the CGuard EPS carotid stent platform. Recent encouraging data from the C-GUARDIANS IDE trial further supports the product's potential as a market leader. Ligotti's extensive background in leadership roles at notable firms strengthens InspireMD's talent pool as they work to serve carotid artery disease patients more effectively.
Read more →NSPR▼ -5.5%on this news
InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard TM Neuroprotection System Reflects continued focus on adding intellectual property to support the strategic direction of the Company to provide a c
InspireMD has announced the issuance of a critical U.S. patent for its SwitchGuardTM Neuroprotection System, which aims to enhance treatment for carotid artery disease and stroke prevention. This patent covers vital components of the system and paves the way for future developments aimed at visualizing blood flow during procedures. The company also plans to submit an Investigational Device Exemption to the FDA in 2024 to support clinical trials. Furthermore, the recent expansion of coverage for carotid artery stenting by the Centers for Medicare and Medicaid Services may broaden the market for InspireMD's products.
Read more →NSPR▲ +6.4%on this news
InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions Study to enroll 15 acute stroke patients acros
InspireMD has entered a strategic agreement with the Jacobs Institute to conduct an Early Feasibility Study for its CGuard EPS. The study will examine the treatment of acute ischemic stroke patients with tandem lesions, marking an important step forward in addressing a gap in current clinical practices. It plans to enroll 15 patients across three U.S. sites. The CEO emphasizes the importance of the CGuard EPS in providing superior embolic protection during acute events.
Read more →NSPRInspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update - Presented positive 30-day follow-up results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) clinical trial demonstrat
InspireMD, Inc. (NSPR) reported its financial results for Q3 2023, highlighting a positive major adverse events rate of 0.95% from the C-GUARDIANS U.S. IDE clinical trial. The company achieved an 8.8% increase in revenue to $1.56 million compared to the previous year. InspireMD received support from CMS for expanding coverage of carotid artery stenting, further enlarging their addressable market. Despite the positive revenue growth, the company's net loss increased to $5.18 million during the quarter, and operating expenses saw a significant rise.
Read more →NSPR▼ -11.4%on this newsshared move
InspireMD to Participate in Upcoming November Investor Conferences
InspireMD, a developer of the CGuard™ Embolic Prevention Stent System, has announced participation in three investor conferences this November. CEO Marvin Slosman will represent the company at the Wolfe Research Healthcare Conference, Canaccord Genuity MedTech Forum, and the Piper 35th Annual Healthcare Conference. Live webcasts of these presentations will be made available on the company's website, reflecting InspireMD's commitment to investor communication and transparency.
Read more →NSPR▲ +11.2%on this newsshared move
InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23 Data demonstrate a low major adverse event rate of 0.95% through 30 days post
InspireMD, Inc. has reported positive 30-day follow-up results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) clinical trial at the VIVA23 conference. The data revealed a low major adverse event rate of just 0.95% within the first 30 days post-procedure, indicating significant safety and efficacy of the CGuard Embolic Prevention Stent System. The trial, which aimed to assess the stent's performance in patients at high risk for carotid endarterectomy, enrolled 316 patients across 24 sites in the U.S. and Europe. The company anticipates sharing 12-month results and contributing to the potential FDA approval process in 2024.
Read more →NSPR▼ -7.1%on this newsshared move
InspireMD to Report Third Quarter 2023 Financial Results and Provide Corporate Business Update on Monday, November 6th
InspireMD, Inc. (Nasdaq: NSPR) announced it will report its third quarter 2023 financial results on November 6, 2023, before markets open. A conference call and webcast will follow at 8:30 a.m. EST to discuss these results and corporate updates. The company aims to utilize its proprietary technology to establish itself as a leader in carotid stenting. However, it faces several risks, including market acceptance issues, competition, and regulatory challenges that could impact its business operations.
Read more →NSPR▲ +12.5%on this news
InspireMD Supports CMS' Final National Coverage Determination (NCD) Expanding Coverage of Carotid Stenting (CAS) to Include Both Asymptomatic and Standard Risk Patients Provides additional treatment options for patients
InspireMD, Inc. has expressed support for the Centers for Medicare and Medicaid Services' final National Coverage Determination which broadens the coverage of carotid artery stenting (CAS) to include asymptomatic patients. This expansion is expected to enhance treatment options and increase the addressable market for CAS and transcarotid artery revascularization (TCAR) procedures. The company continues to focus on advancing its CGuard EPS stent system through regulatory pathways in the U.S. and E.U., bolstered by strong clinical trial outcomes. InspireMD also announced plans to present thirty-day safety results from its latest clinical trial at an upcoming conference.
Read more →NSPRInspireMD Announces Senior Leadership Changes to Support Commercial Growth Initiatives
InspireMD, Inc. has announced significant changes to its senior leadership team to foster its commercial growth strategies. Dr. Patrick Verta has been appointed Executive VP of Clinical and Medical Affairs, while Cheryl Tal will serve as VP of Quality Assurance and Regulatory Affairs. Shane Gleason has been promoted to Chief Commercial Officer. These changes come as the company aims for U.S. regulatory approval of its CGuard Prime carotid stent platform and the development of new stenting technologies to drive future growth.
Read more →NSPR▲ +5.4%on this news
InspireMD Announces Abstract of 30-Day Results from the C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at VIVA23 Tel Aviv, Israel, and Miami, Florida
InspireMD, Inc. (NSPR) announced that an abstract detailing the 30-day results from its C-Guardians U.S. IDE clinical trial has been accepted for presentation at the Vascular InterVentional Advances (VIVA23) conference. The trial evaluates the safety and efficacy of the CGuard Carotid Stent System for treating carotid artery stenosis. The presentation is scheduled for November 1, 2023, by Dr. Chris Metzger, the lead investigator. The company also plans to share one-year data next year that could support a Premarket Approval Application (PMA) for the device.
Read more →NSPRInspireMD Reports Second Quarter 2023 Financial Results and Provides Business Update - Completed transformational private placement for up to $113.6 million, including $42.2 million upfront - - Completed enrollment in th
InspireMD, Inc. (NSPR) reported its financial results for Q2 2023, highlighting key developments including a transformational private placement of up to $113.6 million. The company completed enrollment in its C-Guardians IDE clinical trial and experienced a revenue increase of nearly 10% year-over-year, primarily due to the growth of its CGuard EPS product sales. However, InspireMD also reported a notable net loss for the quarter, accompanied by rising operating expenses, prompting considerations regarding its future capital needs and financial stability.
Read more →NSPRInspireMD to Report Second Quarter 2023 Financial Results and Provide Corporate Business Update on Tuesday, August 8th
InspireMD, Inc. announced its plans to report second quarter 2023 financial results on August 8, 2023, prior to market opening. The company will also host a conference call at 8:30 a.m. EDT on the same day to review these results and discuss corporate developments. The CGuard Embolic Prevention Stent System aims to improve treatment outcomes for Carotid Artery Disease and stroke prevention, although the company faces several market risks and challenges in the healthcare industry.
Read more →NSPR▲ +7%on this news· ran to +22% by day 3
InspireMD Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial Trial designed to support potential U.S. marketing approval of the CGuard Prime EPS stent system Stud
InspireMD has completed enrollment for its C-Guardians U.S. Investigational Device Exemption (IDE) clinical trial, aimed at obtaining marketing approval for the CGuard Prime EPS stent system. The trial enrolled 315 patients across 25 sites in the U.S. and Europe, including first-in-human cases. The company anticipates results from the study in the second half of 2024, with a PMA submission expected shortly thereafter. This development could pave the way for U.S. market entry and increased adoption of the CGuard stent technology.
Read more →NSPRInspireMD Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
InspireMD, Inc. announced the grant of shares and stock options to Shane Gleason, its new General Manager of North America. The grant of 256,450 restricted stock shares and 85,480 stock options was made in connection with his appointment and approved by the company’s Board of Directors. The stock options have a ten-year term with an exercise price reflecting the market price at the time of the grant. This inducement is part of InspireMD's compliance with Nasdaq Listing Rule 5635(c)(4).
Read more →NSPR▼ -8.7%on this newsshared move
InspireMD Reports First Quarter 2023 Financial Results and Provides Business Update - Completed transformational private placement for up to $113.6 million, including $42.2 million upfront - - Generated Q1 2023 CGuard EP
InspireMD reported its first-quarter financial results for 2023, highlighting a successful private placement that raised up to $113.6 million. Revenue from its CGuard EPS reached $1.2 million, marking a 6.7% increase year-over-year, despite challenges due to a temporary expiration of CE Mark certification. The company has resumed shipments to EU countries after regaining its CE Mark under the Medical Device Directive. InspireMD also continues to enroll patients in its U.S. IDE trial, with a completion goal by the end of Q2 2023.
Read more →NSPR▲ +26.9%on this newsshared move
InspireMD Announces Private Placement of Up to $113.6 Million Led by Marshall Wace with participation from OrbiMed, Rosalind, Nantahala, Soleus, Velan and certain InspireMD Board members $42.2 million financing upfront w
InspireMD, Inc. announced a private placement led by Marshall Wace, providing up to $113.6 million in funding, including $42.2 million upfront. The capital aims to support the development of the CGuard Embolic Prevention Stent System and other product advancements. This financing demonstrates strong confidence from several institutional healthcare investors, though the company must navigate potential regulatory and fundraising challenges moving forward.
Read more →NSPRInspireMD Announces May 16, 2023 as New Date for First Quarter 2023 Results Conference Call and Webcast
InspireMD, Inc. has announced that it will host its conference call and webcast on May 16, 2023, to discuss the first quarter 2023 financial and operational results. The call is scheduled to take place at 8:30 a.m. EDT, aiming to provide stakeholders with a comprehensive update. The event is part of the company’s efforts to maintain transparency while navigating various challenges within the medical device industry.
Read more →NSPRInspireMD Announces May 15th as New Date for First Quarter 2023 Financial Results and Corporate Business Update
InspireMD, Inc. has announced that it will report its first quarter 2023 financial results on May 15, 2023. Management will host a conference call at 8:30 AM EDT to discuss the financial results and provide an update on corporate developments. The event will be accessible via a live webcast on the company’s website. InspireMD aims to set industry standards for carotid stenting using its proprietary MicroNet technology.
Read more →NSPR▲ +44.2%on this news
InspireMD Announces Successful First-in-Human Procedure Utilizing CGuard Prime, its Next Generation Carotid Artery Stent (CAS) Platform
InspireMD, Inc. announced the successful first-in-human stenting procedure using its next-generation CGuard Prime stent platform. Performed as part of the ongoing CGuardians U.S. Investigational Device Exemption trial, the procedure signifies a key milestone for the company. InspireMD's CEO expressed pride in the achievement, highlighting the advanced capabilities of the new device, which builds upon existing CGuard technology. The company aims to complete trial enrollment by the end of Q2 2023 and plans to update investors during the upcoming earnings call.
Read more →NSPRInspireMD to Report First Quarter 2023 Financial Results on May 9, 2023, and Provide Corporate Business Update
InspireMD, Inc. announced it will report its first quarter 2023 financial results on May 9, 2023, followed by a corporate update during a conference call. The event signifies the company's ongoing commitment to transparency while engaging with investors. InspireMD is working on the CGuard™ Embolic Prevention Stent System aimed at treating Carotid Artery Disease. However, they face numerous risks, including competition and regulatory challenges.
Read more →NSPR▼ -7.8%on this news
InspireMD Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update - 2022 CGuard EPS revenue of $5.1 million increased 18.9% over 2021 - - Resumed shipments of CGuard EPS to CE Mark territo
InspireMD, Inc. (NSPR) announced its financial results for the fourth quarter and full year of 2022. The company reported a revenue increase in CGuard EPS of 18.9% over the previous year, with a total of $5.1 million generated. However, Q4 revenue decreased by 25.7% year-over-year due to the temporary expiration of its CE Mark, which hampered shipments. Despite these challenges, InspireMD continues enrollment in its C-Guardian US IDE trial, with expectations of regulatory recertification in the near future.
Read more →NSPRInspireMD Announces Promotion of Andrea Tommasoli to Chief Operating Officer Mr. Tommasoli formerly served as the Company's Senior Vice President of Global Sales & Marketing since 2020 and has significant prior commercia
InspireMD, Inc. has announced the promotion of Andrea Tommasoli to Chief Operating Officer. Previously serving as the Senior Vice President of Global Sales & Marketing, Tommasoli has been pivotal in scaling the company’s CGuard Embolic Prevention Stent System across approved EU markets. His extensive commercial leadership experience is expected to support InspireMD's operational growth, particularly as the company aims for U.S. approval with its IDE clinical trial. CEO Marvin Slosman expressed confidence in Tommasoli’s capabilities amidst the company's evolving needs.
Read more →NSPRInspireMD to Report Fourth Quarter and Full-Year 2022 Financial Results on March 30, 2023, and Provide a Corporate Business Update
InspireMD, Inc. (Nasdaq: NSPR) has announced that it will report its fourth quarter and full-year financial results on March 30, 2023, before the market opens. Following the announcement, the company will conduct a conference call and webcast at 8:30 AM EDT to discuss these results and provide a corporate update. The event aims to keep the investment community informed about the company's progress and its CGuard™ Embolic Prevention Stent System for treating carotid artery disease.
Read more →NSPR▲ +6.2%on this news
InspireMD Announces Hiring of Medical Device Commercial Veteran Shane Gleason as General Manager of North America and VP of Global Marketing
InspireMD, Inc. has appointed Shane Gleason as General Manager of North America and VP of Global Marketing, enhancing its leadership team. Gleason, a veteran in the medical device sector, is expected to guide the company as it prepares for the U.S. market launch of its CGuard™ Embolic Prevention Stent System. The announcement comes as InspireMD approaches the completion of its C-Guardian IDE clinical trial and aims to expand its market presence. His extensive experience in vascular interventions positions the company for potential growth and operational success.
Read more →NSPRInspireMD Announces “12 Days of Carotid Stenting” Video Series Featuring Fireside Chats with Top Multidisciplinary Vascular Specialists
TEL AVIV, Israel, Nov. 28, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced a video series, “12 Days of Carotid Stenting,” which will feature leading multidiscipli
Read more →NSPR▲ +6.9%on this news· ran to +21% by day 3
InspireMD Announces Multiple Presentations Featuring CGuard EPS and its Novel MicroNet Mesh Covering at the 2022 VEITH Symposium
TEL AVIV, Israel, Nov. 15, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today announced that the company will deliver multiple presentations at the 2022 VEITH Symposium, which is be
Read more →NSPR▼ -14.8%on this news
InspireMD Reports Third Quarter 2022 Financial Results and Provides Business Update - Generated 38.8% growth in CGuard revenue year-over-year - - Continued enrollment in the C-Guardian US IDE trial, with 24 sites current
Reports Third Quarter 2022 Financial Results and Provides Generated 38.8% growth in CGuard revenue year-over-year - Continued enrollment in the C-Guardian US IDE trial, with 24 sites currently enrolling patients; on track to complete enrollment by approximately Announced strat
Read more →NSPRInspireMD to Report Third Quarter 2022 Financial Results on November 8, 2022, and Provide Corporate Business Update
TEL AVIV, Israel, Oct. 25, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report third quarter 2022 financial
Read more →NSPRInspireMD Announces Presentation at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) Conference
TEL AVIV, Israel, Sept. 13, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today announced that the company will deliver a presentation at the 2022 Transcatheter Cardiovascular Therap
Read more →NSPR▼ -5.9%on this news
InspireMD Reports Second Quarter 2022 Financial Results and Provides Business Update - Generated 47.8% growth in CGuard revenue year-over-year - - Delivered several presentations at LINC 2022 featuring CGuard EPS, includ
Reports Second Quarter 2022 Financial Results and Provides Generated 47.8% growth in CGuard revenue year-over-year - Delivered several presentations at LINC 2022 featuring CGuard EPS, including a successful live case transmission - Announced that endovascular pioneer Dr. Juan
Read more →NSPRInspireMD to Report Second Quarter 2022 Financial Results on August 9, 2022, and Provide Corporate Business Update
- Conference call and webcast to be held at 8:30 a.m. EDT - TEL AVIV, Israel, Aug. 02, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention
Read more →NSPRInspireMD Announces Appointment of Endovascular Pioneer Dr. Juan Parodi as Strategic Advisor
TEL AVIV, Israel, July 14, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today announced the appointment of endovascular pioneer Dr. Juan Parodi as a strategic advisor to the Company
Read more →NSPRInspireMD Provides Highlights from Recent Presentations and Live Case Transmission at LINC 2022
TEL AVIV, Israel, June 09, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today provided the following highlights from multiple presentations and live case transmission, all featuring
Read more →NSPRInspireMD’s CGuard™ Embolic Prevention Stent System to be Featured in Clinical Presentations and a Live Case Transmission at LINC 2022
TEL AVIV, Israel, June 02, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today announced that the company will participate in the Leipzig Interventional Course (LINC) 2022, which is
Read more →NSPRInspireMD Reports First Quarter 2022 Financial Results and Business Update - 20% growth in CGuard revenue Year-over-Year - - C-Guardian FDA IDE Trial Completes First European Enrollment - - Held Key Opinion Leader (KOL)
Reports First Quarter 2022 Financial Results and Business Update 20% growth in CGuard revenue Year-over-Year - C-Guardian FDA IDE Trial Completes First European Enrollment - Held Key Opinion Leader (KOL) Webinar on Carotid Artery Disease Management and Stroke Prevention, highl
Read more →NSPRInspireMD to Report First Quarter 2022 Financial Results on May 10, 2022 and Provide Corporate Business Update
TEL AVIV, Israel, April 28, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report first quarter 2022 financia
Read more →NSPRInspireMD to Host Key Opinion Leader Event on Carotid Artery Disease Management and Stroke Prevention in combination with the CGuard™ Stent Platform & MicroNet™ Portfolio
TEL AVIV, Israel, March 16, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today that it will host a Key Opinion L
Read more →NSPRInspireMD Reports Fourth Quarter and Year-End 2021 Financial Results - CGuard Revenue Generated 87.5% growth over Q4'20 and 55.9% Year-over-Year - - Published CGuard Clinical trial results in Journals of the American Col
Reports Fourth Quarter and Year-End 2021 Financial Results CGuard Revenue Generated 87.5% growth over Q4'20 and 55.9% Year-over-Year - Published CGuard Clinical trial results in Journals of the American College of Cardiology - Established Reimbursement Approval for CGuard from
Read more →NSPRInspireMD Announces the Inclusion of its CGuard Carotid Stent in CREST-2 Trial Following FDA Approval of the Investigational Device Exemption Supplement Application - CGuard Carotid Stent will now be a treatment option i
Announces the Inclusion of its CGuard Carotid Stent in CREST-2 Trial Following FDA Approval of the Investigational Device Exemption Supplement Application CGuard Carotid Stent will now be a treatment option in the stenting plus therapy arm of the trial for patients - CREST-2
Read more →NSPRInspireMD to Report Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022 and Provide Corporate Business Update
-Earnings Conference Call to be held Tuesday, March 8, 2022, at 8:30 a.m. ET- TEL AVIV, Israel, Feb. 22, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CA
Read more →NSPRInspireMD Announces Adnan Siddiqui, MD, PhD as a Member of its Scientific Advisory Board and Strategic Advisor
TEL AVIV, Israel, Feb. 15, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announced the appointment of Adnan Sid
Read more →NSPRInspireMD to Present at the 16th Biennial Scientific Meeting of the International Andreas Gruentzig Society (IAGS)
TEL AVIV, Israel, Jan. 27, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for prevention of stroke caused by Carotid Artery Disease (CAD), today announced that Marvin Slosman, Chief Executive Officer, is sch
Read more →NSPRInspireMD Announces Live Case Broadcast at ISET 2022 Conference Following the Supplement Approval by the FDA Regarding its Pivotal C-Guardians Trial
TEL AVIV, Israel, Jan. 18, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for prevention of stroke caused by Carotid Artery Disease (CAD), today announced that a live case demonstration featuring CGuard™ EPS
Read more →NSPRInspireMD Reports Third Quarter 2021 Financial Results and Provides Corporate Update -CGuard sales generated 24% YoY revenue growth- -CGuard EPS received a positive opinion from the French National Authority for Health (
Reports Third Quarter 2021 Financial Results and Provides Corporate Update sales generated 24% YoY revenue growth- EPS received a positive opinion from the French National Authority for Health (HAS) regarding reimbursement in France- $37.1 million in cash, cash equivalents a
Read more →NSPRInspireMD Announces Publication of 12-Month Results of CGuard EPS SIBERIA Trial in Journals of the American College of Cardiology: Cardiovascular Interventions Tel Aviv, Israel
Announces Publication of 12-Month Results of CGuard EPS SIBERIA Trial in Journals of the American College of Cardiology: Cardiovascular Interventions Aviv, Israel- November 3, 2021 - InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention System (EPS) for t
Read more →NSPRInspireMD to Report Third Quarter 2021 Financial Results on November 9, 2021 and Provide Corporate Business Update
TEL AVIV, Israel, Oct. 26, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announces it will report third quarter 2021 fin
Read more →NSPR▲ +5.1%on this news
InspireMD Receives Reimbursement Approval for CGuard Embolic Prevention System from the French National Authority for Health Tel Aviv, Israel
Receives Reimbursement Approval for CGuard Embolic Prevention System from the French National Authority for Health Aviv, Israel- October 13, 2021 - InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard Embolic Prevention Stent System (EPS) device for the treatment of
Read more →NSPRInspireMD Announces Strong Second Quarter 2021 Financial Results Revenue rebound, strong procedural recovery Management to host investor conference call today
Announces Strong Second Quarter 2021 Financial Results rebound, strong procedural recovery to host investor conference call today, August 10, 2021, at Aviv, Israel- August 10, 2021 - InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention System (EPS) for t
Read more →NSPRInspireMD to Report Second Quarter 2021 Financial Results on Tuesday, August 10, 2021, and Provide Corporate Update
TEL AVIV, Israel, Aug. 04, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announces it will report fiscal first quarter 2
Read more →NSPR▼ -6.7%on this news· ran to -18% by day 3
InspireMD Enrolls and Treats First Patients at Ballad Health System in U.S. Registration C-Guardian Clinical Trial of CGuard EPS Tel Aviv, Israel
Enrolls and Treats First Patients at Ballad Health System in Registration C-Guardian Clinical Trial of CGuard EPS Aviv, Israel- July 23, 2021 - InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention Stent System (EPS) device for the treatment of Carotid Art
Read more →NSPRInspireMD to Present at the LD Micro Virtual Invitational Conference on June 9, 2021
TEL AVIV, Israel, June 02, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq-CM: NSPR) developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by Carotid Artery Disease (CAD), announced today that Chief Executive Officer Marvin Slosman will pre
Read more →NSPRInspireMD Announces Warrants Exchange Listing Transfer to Nasdaq Tickers to be NSPRW and NSPRZ Tel Aviv, Israel
Announces Warrants Exchange Listing Transfer to Nasdaq to be NSPRW and NSPRZ Aviv, Israel- May 27, 2021 - InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CA
Read more →NSPRInspireMD Commences Trading on Nasdaq-CM
TEL AVIV, Israel, May 21, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq-CM: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by Carotid Artery Disease (CAD), today announced that the Company’s shares will commence trading on T
Read more →NSPRInspireMD to Participate at the Investor Summit Conference and Present to Investors on May 17, 2021
TEL AVIV, Israel, May 14, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), announced today that management will participate
Read more →NSPRInspireMD Announces Appointment of Katie Arnold to Board of Directors Tel Aviv, Israel
Announces Appointment of Katie Arnold Aviv, Israel - May 12, 2021 - InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced it has appoi
Read more →NSPRInspireMD Announces First Quarter 2021 Financial Results Company Completes Up-List to Nasdaq Capital Market, with Trading Becoming Effective
Announces First Quarter 2021 Financial Results Completes Up-List to Nasdaq Capital Market, with Trading Becoming Effective May 21, 2021 to host investor conference call today, May 11, 2021, at 8:30am ET Aviv, Israel- May 11, 2021 - InspireMD, Inc. (NYSE American: NSPR), develo
Read more →NSPRInspireMD Announces Stock Exchange Listing Transfer to Nasdaq Ticker to remain NSPR Tel Aviv, Israel
Announces Stock Exchange Listing Transfer to Nasdaq Aviv, Israel- May 10, 2021 - InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announce
Read more →NSPRInspireMD to Participate at the Benzinga Global Small Cap Conference and Present to Investors on May 14, 2021
TEL AVIV, Israel, May 06, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), announced today that management will participate
Read more →NSPRInspireMD to Report First Quarter 2021 Financial Results on Tuesday, May 11, 2021 and Provide Corporate Update
TEL AVIV, Israel, May 04, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) (“InspireMD” or the “Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announces it will repor
Read more →NSPRInspireMD Appoints Acclaimed Interventional Cardiologist Kenneth Rosenfield, MD as Chair of its Newly Formed Scientific Advisory Board
TEL AVIV, Israel, April 29, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid artery disease, today announces the formation of its Scientific Advisory Board w
Read more →NSPRInspireMD Provides Corporate Update for Shareholders Tel Aviv, Israel
Provides Corporate Update for Shareholders Aviv, Israel- April 19, 2021 - InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), to
Read more →NSPRInspireMD Announces 1-for-15 Reverse Stock Split
TEL AVIV, Israel, April 14, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced a 1-for-15
Read more →NSPRInspireMD Announces 1-for-15 Reverse Stock Split Tel Aviv, Israel
Announces 1-for-15 Reverse Stock Split Aviv, Israel- April 14, 2021 - InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today
Read more →NSPRInspireMD CEO Marvin Slosman Issues Letter to Fellow Stockholders Urging Support of the Company’s Plans to List its Common Stock on Nasdaq at the Upcoming Special Meeting of Stockholders
TEL AVIV, Israel, March 22, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid artery disease, today issues a message to stockholders from InspireMD CEO, Marvi
Read more →NSPRInspireMD Announces Fourth Quarter and Year-End 2020 Financial Results
TEL AVIV, Israel, March 09, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced financial and operating resul
Read more →NSPRE xhibit 99.1 InspireMD Announces Fourth Quarter and Year-End 2020 Financial Results Management to host investor conference call today, March 9, at 8:30am ET Tel Aviv, Israel
Announces Fourth Quarter and Year-End 2020 Financial Results to host investor conference call today, March 9, at 8:30am ET Aviv, Israel- March 9, 2021 - InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke
Read more →NSPRInspireMD to Report Fourth Quarter and Year-End 2020 Financial Results on Tuesday, March 9, 2021 and Provide Corporate Update
TEL AVIV, Israel, March 02, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) (“InspireMD” or the “Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announces it will rep
Read more →NSPRInspireMD Engages Hart Clinical Consultants to Conduct Clinical Trial for CGuard Carotid Stent System in the United States
TEL AVIV, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today that it has engaged Hart Clinical Consultants (HCC),
Read more →NSPRInspireMD Appoints Leading Interventional Cardiologist Chris Metzger, M.D. as Principal Investigator for CGuard Registration Trial in the United States
TEL AVIV, Israel, Feb. 09, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today the appointment of Chris Metzger, M.D., system chair
Read more →NSPRInspireMD Announces Closing of an Upsized $20.7 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
TEL AVIV, Israel, Feb. 08, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. ("InspireMD") (NYSE:NSPR), a medical device company focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe
Read more →NSPRINSPIREMD ANNOUNCES PRICING OF UPSIZED $18 MILLION UNDERWRITTEN PUBLIC OFFERING Tel Aviv, Israel /
ANNOUNCES PRICING OF UPSIZED $18 MILLION UNDERWRITTEN PUBLIC OFFERING Aviv, Israel / February 4, 2021 / InspireMD, Inc. ("InspireMD") (NYSE:NSPR), a medical device company focused on the development and commercialization of proprietary MicroNet stent platform technology for the
Read more →NSPRInspireMD Secures Partner for Intended Registration and Distribution of CGuard EPS in Mainland China
TEL AVIV, Israel, Feb. 03, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid artery disease, today announced a transaction intended to achieve distribution of
Read more →NSPRInspireMD’s CGuard™ Featured in Multiple Presentations, Including a Live Case Demonstration During the Leipzig Interventional Congress January 25-29, 2021
TEL AVIV, Israel, Jan. 26, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid artery disease, announced today multiple presentations regarding CGuard EPS, incl
Read more →NSPRInspireMD Announces Third Quarter 2020 Financial Results Third quarter 2020 revenue returns to pre-COVID-19 levels Management to host investor conference call today
Announces Third Quarter 2020 Financial Results quarter 2020 revenue returns to pre-COVID-19 levels to host investor conference call today, November 9, 2020 at 8:30 a.m. ET Aviv, Israel- November 9, 2020 - InspireMD, Inc. (NYSE American: NSPR)("Inspire" or the "Company"), deve
Read more →NSPRInspireMD, Inc. Appoints Andrea Tommasoli Senior Vice President of Global Sales and Marketing and Reports Inducement Grants Under NYSE American Company Guide 711(a) Tel Aviv, Israel
Inc. Appoints Andrea Tommasoli Senior Vice President of Global Sales and Marketing Reports Inducement Grants Under NYSE American Company Guide 711(a) Aviv, Israel - November 3, 2020 - InspireMD, Inc. (NYSE American: NSPR) ("Company"), the developer of the CGuard Embolic Preven
Read more →NSPRInspireMD to Report Third Quarter 2020 Financial Results on Monday, November 9, 2020 and Provide Corporate Update
TEL AVIV, Israel, Nov. 02, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) (“InspireMD” or the “Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announces it will repo
Read more →NSPRInspireMD Announces Renowned Interventional Cardiologist Gary S. Roubin, M.D., Ph.D., to Join Board of Directors Tel Aviv, Israel
Announces Renowned Interventional Cardiologist Gary S. Roubin, M.D., Ph.D., to Join Board of Directors Aviv, Israel - October 13, 2020 - InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by car
Read more →NSPRInspireMD, Inc. Appoints Patrick Jamnik as Vice President of Business Development and Strategic Initiatives and Reports Inducement Grants Under NYSE American Company Guide 711(a) Tel Aviv, Israel
Inc. Appoints Patrick Jamnik as Vice President of Business Development and Strategic Initiatives and Reports Inducement Grants Under NYSE American Company Guide 711(a) Aviv, Israel - October 6, 2020 - InspireMD, Inc. (NYSE American: NSPR) ("Company"), the developer of the CGua
Read more →NSPRInspireMD Announces Christina Brennan, M.D., MBA to Serve in Advisory Role for Pivotal Study of CGuard Carotid Stent System
TEL AVIV, Israel, Sept. 10, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announced the addition of Dr. Christina Brennan as a
Read more →NSPRInspireMD Announces Approval of Investigational Device Exemption (IDE) for Pivotal Study of CGuard Carotid Stent System IDE Approval to Pave the Way for Pivotal Study of CGuard System for Carotid Artery Disease and Strok
Announces Approval of Investigational Device Exemption (IDE) for Pivotal Study of CGuard Carotid Stent System Approval to Pave the Way for Pivotal Study of CGuard System for Carotid Artery Disease and Stroke Prevention in the United States Aviv, Israel - September 8, 2020 - In
Read more →NSPRInspireMD Announces the European Society of Cardiology 2020 "Best Poster Award" for Updated Data from the PARADIGM-EXTEND Study Tel Aviv, Israel
Announces the European Society of Cardiology 2020 "Best Poster Award" for Updated Data from the PARADIGM-EXTEND Study Aviv, Israel - September 3, 2020 - InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard Embolic Prevention System (EPS) for the prevention of stro
Read more →NSPRInspireMD to Present at the LD Micro 500 Virtual Conference on September 3, 2020
TEL AVIV, Israel, Aug. 25, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that Marvin Slosman, President and C
Read more →NSPRInspireMD Regains Compliance with NYSE AMERICAN Listing Standards Tel Aviv, Israel
Regains Compliance with NYSE AMERICAN Listing Standards Aviv, Israel - August 10, 2020 - InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announce
Read more →NSPRInspireMD Announces Second Quarter 2020 Financial Results In the second quarter the Company was granted approval to market its CGuard MicroNet stent in Brazil and completed an $11.5 million capital raise; reported outsta
Announces Second Quarter 2020 Financial Results the second quarter the Company was granted approval to market its CGuard MicroNet stent in Brazil and completed an $11.5 million capital raise; reported outstanding results in studies treating patients with the CGuard MicroNET ste
Read more →NSPRInspireMD to Report Second Quarter 2020 Financial Results on Wednesday, August 5, 2020 and Provide Corporate Update
TEL AVIV, Israel, July 28, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announces it will report fiscal second quarter 2020 f
Read more →NSPRInspireMD Gains Registration Clearance of its CGuard Embolic Prevention System (EPS) in Brazil Tel Aviv, Israel
Gains Registration Clearance of its CGuard Embolic Prevention System (EPS) in Brazil Aviv, Israel - July 23, 2020 - InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (
Read more →NSPRInspireMD Announces Late-Breaking Presentation of Early SIBERIA Clinical Trial Results to be Featured in an e-Course at EuroPCR In a head-to-head evaluation, significantly fewer silent brain infarcts were associated with
Announces Late-Breaking Presentation of Early SIBERIA Clinical Trial Results to be Featured in an e-Course at EuroPCR a head-to-head evaluation, significantly fewer silent brain infarcts were associated with CGuard EPS versus Acculink at 30 days post-procedure Aviv, Israel - J
Read more →NSPRInspireMD Announces Publication of 12-Month Results of CGuard EPS PARADIGM Trial in EuroIntervention Results indicate that 12 months after carotid intervention the CGuard EPS MicroNET-covered stent delivers sustained pro
Announces Publication of 12-Month Results of CGuard EPS PARADIGM Trial in EuroIntervention indicate that 12 months after carotid intervention the CGuard EPS MicroNET-covered stent delivers sustained protection against postprocedural neurologic events Aviv, Israel - June 10, 20
Read more →NSPRInspireMD, Inc. Announces Underwriter Exercise of Over-Allotment Option in Full and Closing of $11.5 Million Follow-On Underwritten Public Offering
TEL AVIV, Israel, June 08, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today the closing, on June 5, 2020, of its $11.5 millio
Read more →NSPRInspireMD, Inc. Announces Pricing of $10 Million Underwritten Public Offering Tel Aviv, Israel
Inc. Announces Pricing of $10 Million Underwritten Public Offering Aviv, Israel- June 3, 2020 - InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, today announced the
Read more →NSPRInspireMD Announces First Quarter 2020 Financial Results First quarter revenue growth driven by continued strong uptake of the CGuard Embolic Prevention System (EPS) in the company's major markets Management to host inve
Announces First Quarter 2020 Financial Results quarter revenue growth driven by continued strong uptake of the CGuard Embolic Prevention System (EPS) in the company's to host investor conference call today, May 12, at 8:30am ET Aviv, Israel- May 12, 2020 - InspireMD, Inc. (NY
Read more →NSPRInspireMD to Report First Quarter 2020 Financial Results and Provide Business Update on Tuesday, May 12
TEL AVIV, Israel, May 05, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today that management will host a conference call and webcas
Read more →NSPRInspireMD Announces Fourth Quarter and Year-End 2019 Financial Results Robust CGuard EPS year-over-year revenue growth of 31% Management to host investor conference call today, March 10, at 8:30am ET Tel Aviv, Israel
Announces Fourth Quarter and Year-End 2019 Financial Results CGuard EPS year-over-year revenue growth of 31% to host investor conference call today, March 10, at 8:30am ET Aviv, Israel- March 10, 2020 - InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Pr
Read more →NSPRInspireMD to Report Fourth Quarter 2019 Financial Results and Provide Business Update on Tuesday, March 10
TEL AVIV, Israel, March 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today that it will host a conference call and webcast on T
Read more →NSPRInspireMD Announces Successful Live Clinical Case Transmissions Featuring CGuard EPS at the Leipzig Interventional Course (LINC) 2020 Case demonstrates ease-of-use and exceptional patient safety features of CGuard EPS Te
Announces Successful Live Clinical Case Transmissions Featuring CGuard EPS at the Leipzig Interventional Course demonstrates ease-of-use and exceptional patient safety features of CGuard EPS Aviv, Israel - January 29, 2020 - InspireMD, Inc. (NYSE American: NSPR), developer of t
Read more →NSPRInspireMD's CGuard Embolic Prevention System to be Prominently Featured in Live Case Transmission at LINC, 28th to the 31st January 2020, in Leipzig, Germany Several Clinical Presentations, Updates, and Panel Discussions
CGuard Embolic Prevention System to be Prominently Featured in Live Case Transmission at LINC, 28th to the 31st January 2020, in Leipzig, Germany Clinical Presentations, Updates, and Panel Discussions on CGuard EPS to also be presented Aviv, Israel- January 27, 2020 - InspireM
Read more →NSPRInspireMD Announces Strong Preliminary Fourth Quarter 2019 Revenue and Reports Inducement Award Under NYSE American Company Guide 711(a) Tel Aviv, Israel
InspireMD Announces Strong Preliminary Fourth Quarter 2019 Revenue and Reports Inducement Award Under NYSE American Company Guide 711(a) Aviv, Israel - January 6, 2020 - InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard Embolic Prevention System (EPS) for the
Read more →NSPRInspireMD Announces Planned Leadership Transition
Life sciences industry veteran Marvin Slosman appointed Chief Executive Officer Appointment adds significant medical technology commercialization experience to the InspireMD team TEL AVIV, Israel, Dec. 10, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the deve
Read more →NSPRInspireMD Announces Planned Leadership Transition Life sciences industry veteran Marvin Slosman appointed Chief Executive Officer Appointment adds significant medical technology commercialization experience to the Inspir
Announces Planned Leadership Transition sciences industry veteran Marvin Slosman appointed Chief Executive Officer adds significant medical technology commercialization experience to the InspireMD team Aviv, Israel - December 10, 2019 - InspireMD, Inc. (NYSE American: NSPR), t
Read more →NSPRInspireMD Reports Updated Positive CGuard EPS Data Presented at VEITH 2019 CGuard EPS clinical data featured as a prominent discussion point in multiple key presentations Data from investigator-initiated multicenter, 729
Reports Updated Positive CGuard EPS Data Presented at VEITH 2019 EPS clinical data featured as a prominent discussion point in multiple key presentations from investigator-initiated multicenter, 729-patient IRONGUARD 2 study suggests that the use of CGuard EPS in routine clinic
Read more →NSPRInspireMD Announces Third Quarter 2019 Financial Results Strong revenue driven by record orders of CGuard EPS Management to host investor conference call today, November 12, at 8:30am ET Tel Aviv, Israel
Announces Third Quarter 2019 Financial Results revenue driven by record orders of CGuard EPS to host investor conference call today, November 12, at 8:30am ET Aviv, Israel- November 12, 2019 - InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention S
Read more →NSPRInspireMD to Report Third Quarter 2019 Financial Results and Provide Business Update on Tuesday, November 12
TEL AVIV, Israel, Nov. 05, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, announced today that it will host a conference call
Read more →NSPRInspireMD, Inc. Announces Pricing of $5 Million Underwritten Public Offering Tel Aviv, Israel
Inc. Announces Pricing of $5 Million Underwritten Public Offering Aviv, Israel- September 19, 2019 - InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, today announced
Read more →NSPRInspireMD Provides Business Update Tel Aviv, Israel
Provides Business Update Aviv, Israel - September 9, 2019 - InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, today provided a business update. CGuard EPS Data Prese
Read more →NSPRInspireMD to Present at the HC Wainwright 21st Annual Global Investment Conference
TEL AVIV, Israel, Sept. 09, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, today announced that James Barry, PhD, Chief Executive Officer and C
Read more →NSPRInspireMD Provides Business Update
TEL AVIV, Israel, Sept. 09, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, today provided a business update. Positive CGuard™ EPS Data Pre
Read more →NSPRInspireMD Announces Notification of NYSE AMERICAN Listing Deficiency Tel Aviv, Israel
Announces Notification of NYSE AMERICAN Listing Deficiency Aviv, Israel - August 9, 2019 - InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announ
Read more →NSPRInspireMD Announces Second Quarter 2019 Financial Results U.S. Investigational Device Exemption (IDE) application submitted to FDA Company to host investor conference call today, August 6, at 8:00am ET Tel Aviv, Israel
Announces Second Quarter 2019 Financial Results Investigational Device Exemption (IDE) application submitted to FDA to host investor conference call today, August 6, at 8:00am ET Aviv, Israel- August 6, 2019 - InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embo
Read more →NSPRInspireMD to Report Second Quarter 2019 Financial Results and Provide Business Update on Tuesday, August 6
TEL AVIV, Israel, July 30, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, announced today that it will host a conference call
Read more →NSPRInspireMD Announces First Quarter 2019 Financial Results On-Track to Submit U.S. IDE expected in Mid-2019 Company to Host Investor Conference Call at 8:00am ET Tel Aviv, Israel
Announces First Quarter 2019 Financial Results to Submit U.S. IDE expected in Mid-2019 to Host Investor Conference Call at 8:00am ET Aviv, Israel- May 14, 2019 - InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention
Read more →NSPRInspireMD to Report First Quarter 2019 Financial Results and Provide Business Update on Tuesday, May 14
TEL AVIV, Israel, May 07, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, announced today that it will host a conference call a
Read more →NSPRInspireMD, Inc. Announces Pricing of $2.4 Million Public Offering of Common Stock
TEL AVIV, Israel, April 04, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced the pricing of its previously annou
Read more →NSPRInspireMD, Inc. Announces Proposed Public Offering of Common Stock Tel Aviv, Israel
Inc. Announces Proposed Public Offering of Common Stock Aviv, Israel - April 3, 2019 - InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced
Read more →NSPRInspireMD Announces 1-for-50 Reverse Stock Split Tel Aviv, Israel
Announces 1-for-50 Reverse Stock Split Aviv, Israel- March 26, 2019 - InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that its Board of Directors
Read more →NSPRInspireMD Announces 1-for-50 Reverse Stock Split
TEL AVIV, Israel, March 26, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that its Board of Directors has approved a one
Read more →NSPRInspireMD Provides Amended Disclosure Tel Aviv, Israel
Provides Amended Disclosure Aviv, Israel - March 22, 2019 - InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today provided an amended disclosure to co
Read more →NSPRInspireMD Provides Amended Disclosure
TEL AVIV, Israel, March 22, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today provided an amended disclosure to conform to
Read more →NSPRInspireMD Announces Fourth Quarter 2018 Financial Results 2018 CGuard TM EPS annual sales increased 55% compared to 2017 On-Track to Submit U.S. IDE in Mid-2019 Company to Host Investor Conference Call at 8:00am ET Tel A
Announces Fourth Quarter 2018 Financial Results CGuardTM EPS annual sales increased 55% compared to 2017 to Submit U.S. IDE in Mid-2019 to Host Investor Conference Call at 8:00am ET Aviv, Israel- February 19, 2019 - InspireMD, Inc. (NYSE American: NSPR), developer of the CGua
Read more →NSPRInspireMD to Report Fourth Quarter and Fiscal 2018 Financial Results and Provide Business Update on Tuesday, February 19 Conference Call Scheduled for 8am Eastern Time Tel Aviv, Israel
to Report Fourth Quarter and Fiscal 2018 Financial Results and Provide Business Update on Tuesday, February 19 Call Scheduled for 8am Eastern Time Aviv, Israel- February 7, 2019 - InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) f
Read more →NSPRInspireMD Announces Presentation of Interim Data from Investigator-Initiated Study Comparing CGuard™ EPS with a Conventional Open-Cell Carotid Stent
CGuard™ EPS shows encouraging interim results verses a conventional carotid stent in absence of any adverse clinical events in the CGuard™ arm Data presented at the LINC 2019 Congress in Leipzig, Germany TEL AVIV, Israel, Jan. 24, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE
Read more →NSPRInspireMD Announces Two Successful Live Clinical Case Transmissions Featuring CGuard EPS at the Leipzig Interventional Course (LINC) 2019 Cases demonstrate ease-of-use of CGuard EPS in two challenging clinical situations
Announces Two Successful Live Clinical Case Transmissions Featuring CGuard EPS at the Leipzig Interventional Course demonstrate ease-of-use of CGuard EPS in two challenging clinical situations physicians face when treating carotid artery Aviv, Israel - January 23, 2019 - Inspir
Read more →NSPRInspireMD Announces Results from Initial Clinical Study of The CGuard™ Embolic Prevention System (EPS) with SmartFit™ Technology
TEL AVIV, Israel, Jan. 22, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced details of a new investigator-initia
Read more →NSPRInspireMD's CGuard Embolic Prevention System to be Prominently Featured in Live Case Transmissions at LINC, 22 nd to the 25 th January 2019, in Leipzig, Germany Several Clinical Presentations, Updates, and Panel Discussi
CGuard Embolic Prevention System to be Prominently Featured in Live Case Transmissions at LINC, 22nd to the 25th January 2019, in Leipzig, Germany Clinical Presentations, Updates, and Panel Discussions on CGuard EPS to also be presented Aviv, Israel- January 18, 2019 - Inspire
Read more →NSPRInspireMD Announces the Distribution of CGuard Embolic Prevention System in South Africa Growing awareness of CGuard EPS among treating physicians, and resulting demand, were key factors driving entry into the South Afri
Announces the Distribution of Embolic Prevention System in South Africa awareness of CGuard EPS among treating physicians, and resulting demand, were key factors driving entry into the South Aviv, Israel- January 14, 2019 - InspireMD, Inc. (NYSE American: NSPR), developer of t
Read more →NSPRInspireMD Receives Noncompliance Notice from NYSE American Tel Aviv, Israel
Receives Noncompliance Notice from NYSE American Aviv, Israel- January 11, 2019 - InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that
Read more →NSPRInspireMD Announces Publication of Meta-Analysis Citing Benefits of Next Generation Mesh-Covered Carotid Stent Systems Analysis includes clinical studies incorporating the Company's MicroNet -covered stent, the CGuard Em
Announces Publication of Meta-Analysis Citing Benefits of Generation Mesh-Covered Carotid Stent Systems includes clinical studies incorporating the Company's MicroNet -covered stent, the Embolic Prevention System (EPS) Aviv, Israel- December 18, 2018 - InspireMD, Inc. (NYSE A
Read more →NSPRInspireMD Announces Positive Long-Term Safety and Efficacy Data from Ongoing CGuard EPS Registries at the Recent 45th Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons (VEITHsymposium) Tel Aviv,
Announces Positive Long-Term Safety and Efficacy Data from Ongoing CGuard EPS Registries at the Recent 45th Annual Symposium on Vascular and Endovascular Issues, Horizons (VEITHsymposium) Aviv, Israel- November 29, 2018 - InspireMD, Inc. (NYSE American: NSPR), developer of th
Read more →NSPRInspireMD Announces Regulatory and Reimbursement Approval of CGuard Embolic Prevention System in Australia Commercial Launch to Occur Immediately Tel Aviv, Israel
Announces Regulatory and Reimbursement Approval of Embolic Prevention System in Australia Launch to Occur Immediately Aviv, Israel- November 28, 2018 - InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke
Read more →NSPRInspireMD Announces Upcoming Presentations at the 45th Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons (VEITHsymposium) Tel Aviv, Israel
Announces Upcoming Presentations at the 45th Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons (VEITHsymposium) Aviv, Israel- November 13, 2018 - InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the pre
Read more →NSPRInspireMD Announces Third Quarter 2018 Financial Results and Provides Corporate Update Presented Three-Year Data Highlighting Long-Term Safety and Efficacy of CGuard Embolic Prevention System On-Track to Submit U.S. IDE
Announces Third Quarter 2018 Financial Results and Provides Corporate Update Three-Year Data Highlighting Long-Term Safety and Efficacy of Embolic Prevention System to Submit U.S. IDE in Mid-2019 to Host Investor Conference Call at 8:00am ET Aviv, Israel - November 6, 2018 -
Read more →NSPRInspireMD to Report Third Quarter 2018 Financial Results and Provide Business Update on Tuesday, November 6
Conference Call Scheduled for 8am Eastern Time TEL AVIV, Israel, Oct. 30, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, ann
Read more →NSPRInspireMD Announces Presentation of Preliminary Cumulative Three-Year CGuard™ EPS Safety and Efficacy Data at the Transcatheter Cardiovascular Therapeutics 2018 Conference
Preliminary Three-Year Data Continue to Show Unprecedented Safety, Efficacy and Durability of Stroke Prevention in Treating Carotid Artery Stenosis TEL AVIV, Israel, Sept. 27, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Preven
Read more →NSPRInspireMD Announces Regulatory Approval of CGuard Embolic Prevention System in Mexico Commercial Launch to Occur Immediately Tel Aviv, Israel
Announces Regulatory Approval of CGuard Embolic Prevention System in Mexico Launch to Occur Immediately Aviv, Israel- September 24, 2018 - InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the
Read more →NSPRInspireMD Announces Issuance of Two New U.S. Patents Covering Proprietary MicroNet Stent Jacket and Related Drug Eluting Technology Patents further strengthen intellectual property surrounding Company's lead commercial p
Announces Issuance of Two New U.S. Patents Covering Proprietary MicroNet Jacket and Related Drug Eluting Technology further strengthen intellectual property surrounding Company's lead commercial product, CGuard EPS remains on track to submit an Investigational Device Exception
Read more →NSPRInspireMD to Present at the H.C. Wainwright 20th Annual Global Investment Conference in New York City
TEL AVIV, ISRAEL, Sept. 04, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE - InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced it will be prese
Read more →NSPRInspireMD Reports 94% Increase in CGuard EPS Revenues for the Second Quarter of 2018 Tel Aviv, Israel
Reports 94% Increase in CGuard EPS Revenues for the Second Quarter of 2018 Aviv, Israel- August 6, 2018 - InspireMD, Inc. (NYSE American:NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery diseas
Read more →NSPRInspireMD Schedules Second Quarter 2018 Earnings Conference Call
Tel Aviv, July 31, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that it will host a conference call on Tuesday, Augus
Read more →NSPRInspireMD Announces Opening of First Two CGuard EPS Centers of Excellence Tel Aviv, Israel
Announces Opening of First Two CGuard EPS Centers of Excellence Aviv, Israel- July 23, 2018 - InspireMD, Inc. (NYSE AMER: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announ
Read more →NSPRInspireMD’s CGuard EPS Featured at the SBHCI Congress in Brazil
Tel Aviv, Israel, June 20, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that CGuard™ EPS was featured at the SBHCI Congress, sponsored by the B
Read more →NSPRInspireMD's CGuard EPS Prominently Featured at the 10th International Congress of the Polish Society for Vascular Surgery Study results presented from 46 patients treated over two years with zero complications President
CGuard EPS Prominently Featured at the 10th International Congress of the Polish Society for Vascular Surgery results presented from 46 patients treated over two years with zero complications of the Polish Society for Vascular Surgery presented clinical cases illustrating the a
Read more →NSPRInspireMD's CGuard MicroNet EPS Featured in a Live Case Transmission to the 2 nd DGA Interventional Congress Tel Aviv, Israel
CGuard MicroNet EPS Featured in a Live Case Transmission to the 2nd DGA Interventional Congress Aviv, Israel- June 11, 2018 - InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today anno
Read more →NSPRInspireMD Reports on Expanded 2 Year Follow-up Results from the PARADIGM Clinical Study Using CGuard EPS
Results Presented at EuroPCR 2018 Confirm Sustained Safety and Cerebral Embolic Prevention out to 24 months TEL AVIV, ISRAEL, May 30, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS), thrombus management technologies and n
Read more →NSPRInspireMD Reports on Expanded 2 Year Follow-up Results from the PARADIGM Clinical Study Using CGuard EPS Results Presented at EuroPCR 2018 Confirm Sustained Safety and Cerebral Embolic Prevention out to 24 months Tel Avi
Reports on Expanded 2 Year Follow-up Results the PARADIGM Clinical Study Using CGuard EPS Presented at EuroPCR 2018 Sustained Safety and Cerebral Embolic Prevention out to 24 months Aviv, Israel- May 24, 2018 - InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention
Read more →NSPRInspireMD Receives Regulatory Approval for both CGuard EPS and MGuard Prime in Ecuador Tel Aviv, Israel
InspireMD Receives Regulatory Approval for and MGuard Prime in Ecuador Aviv, Israel- May 16, 2018 - InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it has receive
Read more →NSPRInspireMD Reports 132% Increase in CGuard EPS Sales for the First Quarter of 2018 Tel Aviv, Israel
Reports 132% Increase in CGuard EPS Sales for the First Quarter of 2018 Aviv, Israel- May 7, 2018 - InspireMD, Inc. (NYSE American:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced results for the
Read more →NSPRInspireMD Schedules First Quarter 2018 Earnings Conference Call
TEL AVIV, ISRAEL , May 01, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it will host a conference call on Monday, May 7th at 4:30 p.m. Eastern
Read more →NSPRInspireMD Announces Regulatory Approval and Reimbursement to Commercialize both CGuard EPS and MGuard Prime Products in Vietnam Tel Aviv, Israel
Announces Regulatory Approval and Reimbursement to Commercialize both CGuard EPS and MGuard Prime Products in Vietnam Aviv, Israel- April 30, 2018 - InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascu
Read more →NSPRInspireMD's CGuard Embolic Prevention System to be Featured at ICCA Stroke 2018 in Warsaw, Poland Tel Aviv, Israel
CGuard Embolic Prevention System to be Featured at ICCA Stroke 2018 in Warsaw, Poland Aviv, Israel- April 19, 2018 - InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that
Read more →NSPRInspireMDs CGuard Embolic Prevention System to be Featured at ICCA Stroke 2018 in Warsaw, Poland
TEL AVIV, ISRAEL, April 19, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that its CGuard™ Embolic Prevention System will be featured at the IC
Read more →NSPRInspireMD Anticipates Fifth Consecutive Quarter of Sequential Double Digit Growth; Projects 132% Increase in CGuard EPS Sales for the First Quarter of 2018; Total Quarterly Company Sales to Exceed $1 Million Tel Aviv, Is
Anticipates Fifth Consecutive Quarter of Sequential Double Digit Growth; 132% Increase in CGuard EPS Sales for the First Quarter of 2018; Total Quarterly Company Sales to Exceed $1 Million Aviv, Israel- April 3, 2018 - InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prev
Read more →NSPRInspireMD, Inc. Announces Pricing of $5.0 Million Public Offering of Common Stock
Tel Aviv, Israel, March 28, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the pricing of an underwritten public offering of 2,857,143 shar
Read more →NSPRInspireMD Receives Regulatory Approval for both CGuard EPS and MGuard Prime in Peru Tel Aviv, Israel
Receives Regulatory Approval for both CGuard EPS and MGuard Prime in Peru Aviv, Israel- March 27, 2018 - InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it has re
Read more →NSPRInspireMD Announces First Patient Treated with CGuard TM EPS in India Patient with severe stenosis, calcification and thrombosis successfully treated with CGuard TM EPS Tel Aviv, Israel
Announces First Patient Treated with CGuardTM EPS in India with severe stenosis, calcification and thrombosis successfully treated with CGuardTM EPS Aviv, Israel- March 5, 2018 - InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus manageme
Read more →NSPRInspireMD Announces Expansion of its Distribution Network Signs Exclusive Distributors for Greece and Caribbean Countries Tel Aviv, Israel
Announces Expansion of its Distribution Network Exclusive Distributors for Greece and Caribbean Countries Aviv, Israel- March 1, 2018 - InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,
Read more →NSPRInspireMD, Inc. Announces Pricing of Public Offering of Common Stock Tel Aviv, Israel
Inc. Announces Pricing of Public Offering of Common Stock Aviv, Israel- February 27, 2018 - InspireMD, Inc. (NYSE American: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the pricing of an underw
Read more →NSPRI nspireMD Announces Exclusive Distribution, Sales and Marketing Agreement for CGuard EPS in South Korea Solvit Medical to fund all regulatory, registration and reimbursement submissions Tel Aviv, Israel
Announces Exclusive Distribution, Sales and Marketing Agreement for CGuard EPS in South Korea Medical to fund all regulatory, registration and reimbursement submissions Aviv, Israel- February 22, 2018 - InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (E
Read more →NSPRInspireMD Announces Exclusive Distribution, Sales and Marketing Agreement for CGuard EPS in South Korea
Solvit Medical to fund all regulatory, registration and reimbursement submissions TEL AVIV, ISRAEL, Feb. 22, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, to
Read more →NSPRInspireMD Announces Commercial Launch and First Sales of CGuard EPS in India Tel Aviv, Israel
Announces Commercial Launch and First Sales of CGuard EPS in India Aviv, Israel- February 20, 2018 - InspireMD, Inc. (NYSE American:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the commercial
Read more →NSPRInspireMD Announces Fourth Quarter and Year-End 2017 Results; CGuard EPS Fourth Quarter Sales Increase 211% Versus Same Period Last year Tel Aviv, Israel
Announces Fourth Quarter and Year-End 2017 Results; CGuard EPS Fourth Quarter Sales Increase 211% Versus Same Period Last year Aviv, Israel- February 14, 2018 - InspireMD, Inc. (NYSE American:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologi
Read more →NSPRInspireMD Announces 1-for-35 Reverse Stock Split
Tel Aviv, Israel, Feb. 07, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced a 1-for-35 reverse split of its common stock, e
Read more →NSPRInspireMD Announces 1-for-35 Reverse Stock Split Tel Aviv, Israel
Announces 1-for-35 Reverse Stock Split Aviv, Israel- February 7, 2018 - InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced a 1-for-35 reverse spli
Read more →NSPRInspireMD's CGuard Embolic Prevention System Featured in Successful Live Case Transmissions at LINC 2018 by Leading Vascular Surgeons Tel Aviv, Israel
CGuard Embolic Prevention System Featured in Successful Live Case Transmissions at LINC 2018 by Leading Vascular Surgeons Aviv, Israel- January 30, 2018 - InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and ne
Read more →NSPRInspireMD's CGuard Embolic Prevention System to be Prominently Featured in Two Live Case Transmissions at LINC 2018 Tel Aviv, Israel
CGuard Embolic Prevention System to be Prominently Featured in Two Live Case Transmissions at LINC 2018 Aviv, Israel- January 26, 2018 - InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,
Read more →NSPRInspireMD Announces Publication of an Independent Imaging Study Highlighting the Advantages of CGuard EPS Compared to Another Next Generation Carotid Stent Tel Aviv, Israel
Announces Publication of an Independent Imaging Study Highlighting the Advantages of CGuard EPS Compared to Another Next Generation Carotid Stent Aviv, Israel- January 19, 2018 - InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus managem
Read more →NSPRCrescendo Communications, llC To: Jim Barry, Craig Shore From: David Waldman, Natalya Rudman Subj: Business Update Call Dial- in: 877-407-0781 I. Introduction - David Waldman Good morning and thank you for joining Inspir
To: Jim Barry, Craig Shore From: David Waldman, Natalya Rudman Subj: Business Update Call Dial- in: 877-407-0781 morning and thank you for joining InspireMD's business update conference call. the call with us today is Jim Barry, Chief Executive Officer of InspireMD and Craig Sh
Read more →NSPRInspireMD Projects 211% Increase in CGuard EPS Sales for the Fourth Quarter of 2017 Conference call to be held at 10AM Eastern today to discuss recent developments, preliminary sales results and proposals for upcoming sh
Projects 211% Increase in CGuard EPS Sales for the Fourth Quarter of 2017 call to be held at 10AM Eastern today to discuss recent developments, preliminary sales results and proposals for upcoming shareholder Aviv, Israel- January 10, 2018 - InspireMD, Inc. (NYSE AMER:NSPR), a
Read more →NSPRInspireMD Projects 211% Increase in CGuard(TM) EPS Sales for the Fourth Quarter of 2017
Conference call to be held at 10AM Eastern today to discuss recent developments, preliminary sales results and proposals for upcoming shareholder meeting Tel Aviv, Israel, Jan. 10, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems
Read more →NSPRInspireMD Announces Regulatory Approval of CGuard EPS in India; Signs Agreement with Leading Indian Medical Device Distributor Tel Aviv, Israel
Announces Regulatory Approval of CGuard EPS in India; Signs Agreement with Leading Indian Medical Device Distributor Aviv, Israel- January 3, 2018 - InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascu
Read more →NSPRInspireMD Schedules Conference Call to Discuss Recent Developments, Preliminary Sales Results and Proposals for Upcoming Shareholder Meeting Tel Aviv
Schedules Conference Call to Discuss Recent Developments, Preliminary Sales Results and Proposals for Upcoming Shareholder Meeting Aviv-January 3, 2018 - InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurov
Read more →NSPRInspireMD's CGuard Embolic Prevention System Once Again Featured in a Successful Live Clinical Case at Leading Industry Conference Professor Pierfrancesco Veroux treated a patient with carotid artery disease using CGuard
CGuard Embolic Prevention System Once Again Featured in a Successful Live Clinical Case at Leading Industry Conference Pierfrancesco Veroux treated a patient with carotid artery disease using CGuard EPS Aviv, Israel- December 18, 2017 - InspireMD, Inc. (NYSE AMER:NSPR), a le
Read more →NSPRInspireMD’s CGuard EPS Demonstrates Improved Outcomes over Carotid Endarterectomy in 50 Patient Comparative Study; Preliminary Results Featured at the 7th Munich Vascular Conference 2017
TEL AVIV, ISRAEL, Dec. 07, 2017 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that Professor Ralf Kolvenbach, head of the Vascular Surgery and End
Read more →NSPRInspireMD Announces Preliminary 2 Year Follow-up Results from the PARADIGM Clinical Study Using CGuard EPS No procedure or device related adverse events at 24 months Results presented at the 2017 VEITHsymposium in New Yo
Announces Preliminary 2 Year Follow-up Results from the PARADIGM Clinical Study Using CGuard EPS procedure or device related adverse events at 24 months presented at the 2017 VEITHsymposium in New York ICI Meeting 2017 in Tel Aviv Aviv, Israel- December 5, 2017 - InspireMD,
Read more →NSPRInspireMD Announces Expansion of its Distribution Network for CGuard EPS in Australia, New Zealand and Vietnam Tel Aviv, Israel
Announces Expansion of its Distribution Network for CGuard EPS in Australia, New Zealand and Vietnam Aviv, Israel- December 4, 2017 - InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, to
Read more →NSPRInspireMD Announces Planned Recapitalization Tel Aviv, Israel
Announces Planned Recapitalization Aviv, Israel- November 29, 2017 - InspireMD, Inc. (NYSE MKT:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it entered into a securities purchase agreement
Read more →NSPRInspireMD Announces Planned Recapitalization
TEL AVIV, ISRAEL--(Marketwired - Nov 29, 2017) - InspireMD, Inc. (NYSE MKT: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it entered into a securities purchase agreement with an institutional
Read more →NSPRInspireMD Announces Third Quarter 2017 Results; CGuard Revenue Increases 90% Versus Same Period Last year Tel Aviv, Israel
Announces Third Quarter 2017 Results; CGuard Revenue Increases 90% Versus Same Period Last year Aviv, Israel-November 7, 2017 - InspireMD, Inc. (NYSE AMER:NSPR), a leader in Embolic Prevention Systems (EPS) / thrombus management technologies and neurovascular devices, today an
Read more →NSPRInspireMD Schedules Third Quarter 2017 Earnings Conference Call
TEL AVIV, ISRAEL--(Marketwired - Nov 1, 2017) - InspireMD, Inc. (NYSE American: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it will host a conference call on Wednesday, November 8th at 8:00
Read more →NSPRInspireMD's CGuard(TM) Carotid Embolic Prevention System Featured in Live Case at Cracow Vascular Summit 2017 in Poland
TEL AVIV, ISRAEL--(Marketwired - Oct 25, 2017) - InspireMD, Inc. (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) (NYSE American: NSPR) (NYSE American: NSPR.WS), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that Pr
Read more →NSPRNew York Stock Exchange Accepts InspireMD's Plan to Regain Compliance Tel Aviv, Israel
York Stock Exchange Accepts InspireMD's Plan to Regain Compliance Aviv, Israel - October 24, 2017 - InspireMD, Inc. (NYSE AMER:NSPR) (NYSE AMER:NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovasc
Read more →NSPRInspireMD Announces Distribution Agreement for MGuard Prime(TM) in Chile
TEL AVIV, ISRAEL--(Marketwired - Oct 12, 2017) - InspireMD, Inc. (NYSE American: NSPR) (NYSE MKT: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it has signed an agreement with CorpMedical Chile Lt
Read more →NSPRInspireMD Announces the Start of Patient Enrollment in an Investigator Initiated Trial of CGuard EPS in Russia CGuard Embolic Prevention System (EPS) to be Randomized Against Abbott's RX ACCULINK Carotid Stent System Tel
Announces the Start of Patient Enrollment in an Investigator Initiated Trial of CGuard EPS in Russia Embolic Prevention System (EPS) to be Randomized Against Abbott's RX ACCULINK Carotid Stent System Aviv, Israel-October 9, 2017 - InspireMD, Inc. (NYSE AMER:NSPR), a leader in
Read more →NSPRInspireMD Postpones Special Meeting of Stockholders to
Postpones Special Meeting of Stockholders to October 27, 2017 Aviv, Israel-October 4, 2017 - InspireMD, Inc. (NYSE AMER:NSPR) (NYSE AMER:NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular
Read more →NSPRInspireMD Announces Distribution Agreement for CGuard TM EPS in Portugal Tel Aviv, Israel
Announces Distribution Agreement CGuardTM EPS in Portugal Aviv, Israel-September 21, 2017 - InspireMD, Inc. (NYSE AMER:NSPR) (NYSE AMER:NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular de
Read more →NSPRInspireMD to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City
TEL AVIV, ISRAEL--(Marketwired - Sep 6, 2017) - InspireMD, Inc. (NYSE American: NSPR) (NYSE American: NSPR.WS) (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular de
Read more →NSPRInspireMD Announces Distribution Agreement for CGuard TM EPS in Switzerland Tel Aviv, Israel
Announces Distribution Agreement for CGuardTM EPS in Switzerland Aviv, Israel-August 25, 2017 - InspireMD, Inc. (NYSE AMER:NSPR) (NYSE AMER:NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascula
Read more →NSPRInspireMD Announces Notification of NYSE AMERICAN Listing Deficiency and Expectation to Regain Compliance
TEL AVIV, ISRAEL--(Marketwired - Aug 22, 2017) - InspireMD, Inc. (NYSE American: NSPR) (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it received a letter
Read more →NSPRInspireMD Shares CGuard TM EPS Video Testimonials from European Key Opinion Leaders Tel Aviv
Shares CGuardTM EPS Video Testimonials from European Key Opinion Leaders Aviv-August 22, 2017 - InspireMD, Inc. (NYSE AMER:NSPR) (NYSE AMER:NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascula
Read more →NSPRInspireMD Reports Double Digit Sequential and Year-Over-Year Revenue Growth for the Second Quarter of 2017 Completes Transition to Local Distribution Network Across Europe CGuard Sales in European Countries Transitioned
Reports Double Digit Sequential and Year-Over-Year Revenue Growth for the Second Quarter of 2017 Transition to Local Distribution Network Across Europe Sales in European Countries Transitioned Back from Former Distributor Increase 122% Versus Q1 2017 Aviv-August 8, 2017 - Insp
Read more →NSPRInspireMD Announces Publication of an Independent Clinical Review Authored by Leading U.S. and European Physicians Supporting Safety Advantages of Mesh-Covered Carotid Stents Comprehensive Review of Clinical Trial Data S
Announces Publication of an Independent Clinical Review Authored by Leading U.S. and European Physicians Supporting Safety Advantages of Mesh-Covered Carotid Stents Review of Clinical Trial Data Supports the Safety and Efficacy of Carotid Artery Stenting (CAS) Versus Carotid En
Read more →NSPRInspireMD's CGuard Carotid Embolic Prevention System Featured at the SOLACI CACI Congress of Cardiology 2017 in Buenos Aires CGuard TM EPS procedure recorded and broadcast to the entire congress Tel Aviv, Israel
CGuard Carotid Embolic Prevention System Featured at the SOLACI CACI Congress of Cardiology 2017 in Buenos Aires EPS procedure recorded and broadcast to the entire congress Aviv, Israel - August 3, 2017 - InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) ("InspireMD" or the
Read more →NSPRInspireMD Schedules Second Quarter 2017 Earnings Conference Call
TEL AVIV, ISRAEL--(Marketwired - Aug 2, 2017) - InspireMD, Inc. (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it will host a conf
Read more →NSPRInspireMD Announces Completion of Transition from Exclusive European Distributor to InspireMD Managed Local Distribution Network Agreements Completed with Leading Distributors in Austria and Belgium Tel Aviv, Israel
Announces Completion of Transition from Exclusive European Distributor to InspireMD Managed Local Distribution Network Completed with Leading Distributors in Austria and Belgium Aviv, Israel-June 13, 2017 - InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) ("InspireMD" or the
Read more →NSPRInspireMD to Present at the 2017 Marcum Microcap Conference
TEL AVIV, ISRAEL--(Marketwired - Jun 9, 2017) - InspireMD, Inc. (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it will be presenting at
Read more →NSPRInspireMD Announces Distribution Agreement for CGuard EPS in Taiwan Tel Aviv, Israel
Announces Distribution Agreement for CGuard EPS in Taiwan Aviv, Israel-June 8, 2017 - InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, to
Read more →NSPRInspireMD Announces the Publication of an Investigator Initiated Clinical Registry Reaffirming MGuard TM Prime as a Highly Effective Tool to Prevent Heart Damage in Coronary Artery Blockages with High Thrombotic Content
Announces the Publication of an Investigator Initiated Clinical Registry Reaffirming MGuardTM Prime as a Highly Effective Tool to Prevent Heart Damage in Coronary Artery Blockages with High Thrombotic Content Entitled "Long term Outcomes of MGuard Stent Deployment in Saphenous
Read more →NSPRInspireMD Announces Distribution Agreement for CGuard TM EPS in Poland Tel Aviv, Israel
Announces Distribution Agreement for CGuardTM EPS in Poland Aviv, Israel-June 5, 2017 - InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,
Read more →NSPRInspireMD Announces Appointment of Paul Stuka as Chairman of the Board Tel Aviv, Israel
Announces Appointment of Stuka as Chairman of the Board Aviv, Israel-June 2, 2017 - InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, tod
Read more →NSPRInspireMD Announces First Two Patients in Hong Kong Successfully Treated with CGuard EPS Tel Aviv, Israel
Announces First Two Patients in Hong Kong Successfully Treated with CGuard EPS Aviv, Israel-May 30, 2017 - InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neu
Read more →NSPRInspireMD's CGuard Carotid Embolic Prevention System Featured in Live Case Transmission at EuroPCR 2017 Prof. Alberto Cremonesi's team performed successful case treating a patient with carotid artery disease with CGuard
CGuard Carotid Embolic Prevention System Featured in Live Case Transmission at EuroPCR 2017 Alberto Cremonesi's team performed successful case treating a patient with carotid artery disease with CGuard Aviv, Israel - May 18, 2017 - InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NS
Read more →NSPRInspireMD Announces Publication of the IRON-GUARD Registry in EuroIntervention Zero incidence of major adverse cardiovascular events including no major strokes BOSTON, MA
Announces Publication of the IRON-GUARD Registry in EuroIntervention incidence of major adverse cardiovascular events including no major strokes MA-May 17, 2017 - InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic preventio
Read more →NSPRInspireMD Announces Distribution Agreements for CGuard EPS and MGuard Prime EPS in Peru and Ecuador BOSTON, MA
Announces Distribution Agreements for CGuard EPS and MGuard Prime EPS in Peru and Ecuador MA-May 15, 2017 - InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neu
Read more →NSPRInspireMD Provides Business Update for the First Quarter of 2017 New Commercial Roll-Out of CGuard EPS on Schedule 84% Sequential Increase in Sales of CGuard Tel Aviv
Provides Business Update for the First Quarter of 2017 Commercial Roll-Out of CGuard EPS on Schedule Sequential Increase in Sales of CGuard Aviv-May 9, 2017 - InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention sys
Read more →NSPRInspireMD Announces Distribution Agreement for CGuard TM EPS in Germany Tel Aviv
Announces Distribution Agreement for CGuardTM EPS in Germany Aviv-May 1, 2017 - InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today a
Read more →NSPRInspireMD Announces Listing of Series B Warrants on the NYSE MKT Tel Aviv
Announces Listing of Series B Warrants Aviv-April 5, 2017 - InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the listing
Read more →NSPRInspireMD Announces Commercial Launch of CGuard EPS in the Russian Federation at the ICCA Stroke Event In Moscow BOSTON, MA
Announces Commercial Launch of CGuard EPS in the Federation at the ICCA Stroke Event In Moscow MA-March 30, 2017 - InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies
Read more →NSPRInspireMD Repays Term Note Ahead of Schedule Tel Aviv
Repays Term Note Ahead of Schedule Aviv-March 22, 2017 - InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it has re
Read more →NSPRInspireMD Announces CGuard TM Distribution Agreement for the Russian Federation Tel Aviv
Announces CGuardTM Distribution Agreement for the Russian Federation Aviv-March 20, 2017 - InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular device
Read more →NSPRInspireMD Announces Closing of Public Offering of Approximately $6.8 Million BOSTON, MA
Announces Closing of Public Offering of Approximately $6.8 Million MA - March 14, 2017 - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced
Read more →NSPRInspireMD Announces Pricing of Public Offering of up to $7.5 Million BOSTON, MA
Announces Pricing of Public Offering of up to $7.5 Million MA - March 9, 2017 - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the prici
Read more →NSPRInspireMD Provides Year End Business Update and Reports Financial Results for the Fourth Quarter and Year Ended
Provides Year End Business Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016 from Exclusive Distribution Partner to Local Distributors and Internal Sales Strategy Validated by Strong Revenue Growth in Select MA-February 16, 2017 - In
Read more →NSPRInspireMD Announces Change in Presentation Time at LD Micro Main Event Conference to Tuesday, December 6 at 4:30PM PT
BOSTON, MA--(Marketwired - Dec 5, 2016) - InspireMD, Inc. (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced a change in the Company's prese
Read more →NSPRInspireMD to Present at LD Micro Main Event on December 6
BOSTON, MA--(Marketwired - Nov 28, 2016) - InspireMD, Inc. (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced that Chief Financial Officer C
Read more →NSPRInspireMD Announces CGuard(TM) Embolic Prevention System Commercialization Approval in Russia
BOSTON, MA--(Marketwired - Nov 14, 2016) - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced that it has received regulatory approval to commer
Read more →NSPRInspireMD Reports Financial Results for the Third Quarter Ended
Reports Financial Results for the Third Quarter Ended September 30, 2016 Company to Host Conference Call Today at 4:30pm ET - MA - November 14, 2016 - InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurov
Read more →NSPRInspireMD to Report Third Quarter Financial Results on Monday, November 14, 2016
BOSTON, MA--(Marketwired - Nov 7, 2016) - InspireMD, Inc. (NYSE MKT: NSPR.WS), a leader in embolic protection systems, announced today that it will release its financial results for the third quarter ended September 30, 2016 on Monday, November 14 after the market close, followed
Read more →NSPRInspireMD CGuard(TM) Embolic Prevention System 12-Month Clinical Trial Data Further Validate Potential of CGuard(TM) to Improve Management of Carotid Artery Disease and Prevent Stroke
BOSTON, MA--(Marketwired - Nov 1, 2016) - InspireMD, Inc. (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced 12-month follow up data from PA
Read more →NSPRInspireMD Announces Appointment of Medical Device Industry Veteran Agustin Gago as Chief Commercial Officer BOSTON, MA
Announces Appointment of Medical Device Industry Veteran Gago as Chief Commercial Officer MA - October 26, 2016 - InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus manageme
Read more →NSPRInspireMD Announces Independent Study Published in the Journal of Endovascular Therapy that Continues to Support the Clinical Benefit and Utility of the CGuard Embolic Prevention System 100% procedural success rate in a
Announces Independent Study Published in the Journal of Endovascular Therapy that Continues to Support the Clinical Benefit the CGuard Embolic Prevention System procedural success rate in a 30 patient study using the new CGuardTM Embolic Prevention System with no procedural re
Read more →NSPRInspireMD to Present at the Dawson James Securities 2nd Annual Growth Stock Conference on October 20
BOSTON, MA--(Marketwired - Oct 13, 2016) - InspireMD, Inc. (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced that President and Chief Execu
Read more →NSPRInspireMD Announces Adjustments to Shares Receivable Upon Warrant Exercise and Exercise Price Per Share BOSTON, MA
Announces Adjustments to Shares Receivable Upon Warrant Exercise and Exercise Price Per Share MA - October 6, 2016 - InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus manage
Read more →NSPRInspireMD Announces 1-for-25 Reverse Stock Split BOSTON, MA
Announces 1-for-25 Reverse Stock Split MA - September 28, 2016 - InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced a 1-for-25 rever
Read more →NSPRInspireMD Announces 1-for-25 Reverse Stock Split
BOSTON, MA--(Marketwired - Sep 28, 2016) - InspireMD, Inc. (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced a 1-for-25 reverse split of it
Read more →NSPRInspireMD Appoints Thomas Kester to Board of Directors BOSTON, MA
Appoints Thomas Kester to Board of Directors MA - September 7, 2016 - InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced the appoint
Read more →NSPRInspireMD Reports Financial Results for the Second Quarter Ended
Reports Financial Results for the Second Quarter Ended - Company to Host Conference Call Today at MA - August 9, 2016 - InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus ma
Read more →NSPRInspireMD to Report Second Quarter Financial Results on Tuesday, August 9, 2016
BOSTON, MA--(Marketwired - Aug 2, 2016) - InspireMD, Inc. (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS), a leader in embolic protection systems, announced today that it will release its financial results for the second quarter ended June 30, 2016 on Tuesday, August 9 after the market clos
Read more →NSPRInspireMD Announces Listing of Warrants on the NYSE MKT
BOSTON, MA--(Marketwired - Aug 1, 2016) - InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic protection systems (EPS), neurovascular devices and thrombus management technologies, today announced the listing of the Company's 44,242,424 pr
Read more →NSPRInspireMD Regains Compliance with NYSE MKT Listing Standards BOSTON, MA
Compliance with NYSE MKT Listing Standards BOSTON, MA - July 21, 2016 - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection systems (EPS), neurovascular devices and thrombus management technologies, today announced that the NYSE MKT
Read more →NSPRInspireMD Announces Closing of Public Offering of Approximately $14.6 Million BOSTON, MA
InspireMD Announces Closing of Public Offering of Approximately $14.6 Million BOSTON, MA - July 7, 2016 - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies,
Read more →NSPRInspireMD Announces Pricing of Public Offering of Approximately $14.6 Million BOSTON, MA
Announces Pricing of Public Offering of Approximately $14.6 Million BOSTON, MA - June 30, 2016 - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today ann
Read more →NSPRInspireMD Announces Amendment to Loan & Security Agreement with Hercules Capital Principal Payments Deferred, Assisting Cash Management Programs BOSTON, MA
InspireMD Announces Amendment to Loan & Security Agreement with Hercules Capital Principal Payments Deferred, Assisting Cash Management Programs MA - June 14, 2016 - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS)
Read more →NSPRInspireMD Names Dr. James Barry as President and CEO Medical Device Veteran Brings Broad Industry Experience in Pioneering Technologies BOSTON, MA
Names Dr. James Barry as President and CEO Medical Device Veteran Brings Broad Industry Experience in Pioneering Technologies BOSTON, MA - June 7, 2016 - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascu
Read more →NSPRInspireMD's CGuard TM Highlighted at the Late-Breaking Clinical Trial Session at the EuroPCR 2016 Conference BOSTON, MA
CGuardTM Highlighted at the Late-Breaking Clinical Trial Session at the EuroPCR 2016 Conference BOSTON, MA - May 17, 2016 - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus managem
Read more →NSPRInspireMD Reports Financial Results for the First Quarter Ended
InspireMD Reports Financial Results for the First Quarter Ended March 31, 2016 BOSTON, MA - May 10, 2016 - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies
Read more →NSPRInspireMD Announces Late-Breaking Trial Presentation on CGuard(TM) Embolic Prevention System at EuroPCR 2016 Conference
BOSTON, MA--(Marketwired - May 5, 2016) - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced that CGuard EPS will be featured at the Late-Breaki
Read more →NSPRInspireMD Receives Audit Opinion With Going Concern Explanation
BOSTON, MA--(Marketwired - Mar 31, 2016) - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced that as previously disclosed in its Annual Report
Read more →NSPRInspireMD Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2015
BOSTON, MA--(Marketwired - Mar 28, 2016) - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced its financial and operating results for the fourth
Read more →NSPRInspireMD Announces Closing of Public Offering
BOSTON, MA--(Marketwired - Mar 21, 2016) - InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection systems ("EPS"), today announced the closing of an underwritten public offering of 1,900,000 shares of its common stock and warrants to purch
Read more →NSPRInspireMD Announces Closing of Private Placement to Certain Officers and Directors
BOSTON, MA--(Marketwired - Mar 21, 2016) - InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection systems ("EPS"), today announced the closing of its private placement of 1,033,051 shares of its common stock and warrants to purchase up to
Read more →NSPRInspireMD Announces Pricing of Public Offering BOSTON, MA
InspireMD Announces Pricing of Public BOSTON, MA - March 16, 2016 - InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection systems ("EPS"), today announced the pricing of an underwritten public offering of 1,900,000 shares of its common
Read more →NSPRInspireMD Announces Pricing of Public Offering
BOSTON, MA--(Marketwired - Mar 16, 2016) - InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection systems ("EPS"), today announced the pricing of an underwritten public offering of 1,900,000 shares of its common stock and warrants to purch
Read more →NSPRInspireMD Announces Private Placement to Certain Officers and Directors
BOSTON, MA--(Marketwired - Mar 16, 2016) - InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection systems ("EPS"), today announced a private placement (the "Private Placement") of up to 1,100,000 shares of its common stock and warrants to
Read more →NSPRInspireMD Announces Proposed Public Offering of Common Stock and Warrants
BOSTON, MA--(Marketwired - Mar 15, 2016) - InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection systems ("EPS"), today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and wa
Read more →NSPRInspireMD Aligns Operations and Leadership Team, Appoints Isaac Blech as Vice Chairman of the Board - Enhances Commercial and Development Execution - Reduces Operating Cost Structure - Strengthens Board of Directors BOST
Aligns Operations and Leadership Team, Appoints Isaac Blech as Vice Chairman of the Board Commercial and Development Execution Operating Cost Structure MA - January 22, 2016 - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention syst
Read more →NSPRInspireMD Receives EU Regulatory Approval for Additional Supplier of CGuard TM Delivery Catheters BOSTON, MA
Receives EU Regulatory Approval for Additional Supplier of CGuardTM Delivery Catheters BOSTON, MA - December 2, 2015 - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management t
Read more →NSPRInspireMD Announces Positive Twelve Month Follow-Up CARENET Trial Data at VEITH Symposium 2015 BOSTON, MA
Announces Positive Twelve Month Follow-Up CARENET Trial Data at VEITH Symposium 2015 BOSTON, MA - November 20, 2015 - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management t
Read more →NSPRInspireMD to Report Financial Results for the Third Quarter Ended September 30, 2015 on Tuesday, November 10th
BOSTON, MA--(Marketwired - Nov 2, 2015) - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced today that it will release its full financial results for
Read more →NSPRInspireMD Announces CGuard TM Approval in Argentina CGuard TM Clinical Data Presented at TCT 2015 Carotid Scientific Sessions BOSTON, MA
Announces CGuardTM Approval in Argentina Clinical Data Presented at TCT 2015 Carotid Scientific Sessions MA - October 19, 2015 - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus ma
Read more →NSPRInspireMD Announces CGuardTM Approval in Argentina
BOSTON, MA--(Marketwired - Oct 19, 2015) - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced today that it has received regulatory approval to commer
Read more →NSPRNYSE MKT: NSPR October 2015 Forward Looking Statements 2 This presentation contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates,"
NYSE MKT: NSPR October 2015 Forward Looking Statements 2 This presentation contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "h
Read more →NSPRInspireMD to Present at Dawson James Securities Growth Stock Conference
BOSTON, MA--(Marketwired - Oct 8, 2015) - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced today that Chief Executive Officer, Alan Milinazzo, will
Read more →NSPRInspireMD Announces CGuard(TM) Approval in Columbia
BOSTON, MA--(Marketwired - Oct 5, 2015) - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced today that it has received regulatory approval to commerc
Read more →NSPRInspireMD Announces CGuard TM Approval in Colombia BOSTON, MA
Announces CGuardTM Approval in Colombia MA - October 5, 2015 - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced today that it has received regula
Read more →NSPRInspireMD Announces One-for-Ten Reverse Stock Split BOSTON, MA
Announces One-for-Ten Reverse Stock Split MA - October 1, 2015 - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced today a one-for-ten reverse spl
Read more →NSPRInspireMD Announces Full Market Launch of CGuard(TM) Distributed by Penumbra at CIRSE Annual Congress
BOSTON, MA--(Marketwired - Sep 28, 2015) - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced today the full market launch of the CGuard Embolic Preve
Read more →NSPRInspireMD Announces the Issuance of Two United States Patents
BOSTON, MA--(Marketwired - Sep 17, 2015) - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced today that the United States Patent & Trademark Office h
Read more →NSPRInspireMD Announces Allowance of US Patent Claims
BOSTON, MA--(Marketwired - Sep 9, 2015) - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced today that the United States Patent & Trademark Office ha
Read more →NSPRNYSE MKT: NSPR September 2015 Forward Looking Statements 2 This presentation contains "forward - looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipate
NYSE MKT: NSPR September 2015 Forward Looking Statements 2 This presentation contains "forward - looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes,
Read more →NSPRP rospective evaluation of A ll - comer pe R cutaneous c A roti D revascularization I n symptomatic and increased - risk asymptomatic carotid artery stenosis using C G uard M icronet - covered embolic prevention stent sy
P rospective evaluation of A ll - comer pe R cutaneous c A roti D revascularization I n symptomatic and increased - risk asymptomatic carotid artery stenosis using C G uard M icronet - covered embolic prevention stent system : The PARADIGM Study Jagiellonian University Dept. of C
Read more →NSPRAnnounces Clinical Presentations on CGuard and MGuard
Announces Clinical Presentations on CGuard and MGuard Systems with MicroNetTM Technology at EuroPCR 2015 Conference Clinical Presentations Highlight Carotid and Coronary Applications of InspireMD's Proprietary MicroNetTM Technology BOSTON, MA - May 12, 2015 - InspireMD, Inc
Read more →NSPRInspireMD Announces MGuard Prime Approval in Brazil BOSTON, MA
InspireMD Announces MGuard Prime BOSTON, MA - April 27, 2015 - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in stent embolic protection systems ("EPS"), today announced it received approval to commercialize MGuard Prime with MicroNet technology in
Read more →NSPRCompletion of Sales Restructuring Program
Completion of Sales Restructuring Program - April 15, 2015 - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in stent embolic protection systems ("EPS"), today announced the completion of its sales restructuring program which began on January 4, 2015.
Read more →NSPRInspireMD Plan of Compliance Accepted by
Compliance Accepted by NYSE MKT BOSTON, MA - March 16, 2015 - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection systems ("EPS"), announced today that the New York Stock Exchange has accepted InspireMD's plan to regain compliance wi
Read more →NSPRInspireMD Reports Financial Results for the
InspireMD Reports Financial Results for the Fourth Quarter and Year Ended BOSTON, MA - March 12, 2015 - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in stent embolic protection systems ("EPS"), today announced its financial and operating results f
Read more →NSPRInspireMD Announces Closing of Public Offering for Approximately $13.7 Million BOSTON, MA
InspireMD Announces Closing of Public Offering for Approximately $13.7 Million BOSTON, MA - March 9, 2015 - InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection systems ("EPS"), today announced the closing of its offering of approxim
Read more →NSPRInspireMD Announces Public Offering for Approximately $13.5 Million BOSTON, MA
InspireMD Announces Public Offering for Approximately $13.5 Million BOSTON, MA - March 4, 2015 - InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection systems ("EPS"), today announced that it has entered into a definitive agreement to
Read more →NSPRInspireMD Announces Proposed Public Offering of Common Stock and Warrants BOSTON, MA
InspireMD Announces Proposed Public Offering of Common Stock and Warrants BOSTON, MA - March 3, 2015 - InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection systems ("EPS"), today announced that it intends to offer and sell, subject t
Read more →NSPRNYSE MKT: NSPR February 2015
NYSE MKT: NSPR February 2015 Forward Looking Statements 2 This presentation contains "forward - looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes,"
Read more →NSPRPiotr Musialek , MD DPhil FESC Jagiellonian University Dept. of Cardiac & Vascular Diseases John Paul II Hospital , Krakow , Poland 2015 The CARENET all - comer trial using the CGuard micronet - covered carotid embolic p
Piotr Musialek , MD DPhil FESC Jagiellonian University Dept. of Cardiac & Vascular Diseases John Paul II Hospital , Krakow , Poland 2015 The CARENET all - comer trial using the CGuard micronet - covered carotid embolic prevention stent 6 month data CAS: State - of - the - art an
Read more →NSPRNotification of NYSE MKT Listing Deficiency
Notification of NYSE MKT Listing Deficiency BOSTON, MA - January 21, 2015 - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection systems ("EPS"), today announced the receipt of a notice indicating that InspireMD does not meet certain
Read more →NSPRInspireMD to Announce Positive Six Month Results from the CGuard TM CARENET Trial at LINC 2015 CGuard TM All Comer Data Continues to Show Excellent Clinical Benefits of the MicroNet TM Covered Technology Six-Month Ultras
InspireMD to Announce Positive Six Month Results from the CARENET Trial at LINC 2015 All Comer Data Continues to Show Excellent of the MicroNetTM Covered Technology Six-Month Ultrasound Analysis is Indicative of Patent Carotid Arteries Concern When Compared to Conventional
Read more →NSPRInspireMD Pre-Announces a Fourth Quarter
InspireMD Pre-Announces a Fourth Quarter 2014 Revenue Increase of 200% Over the Third Quarter of 2014 and Provides Update on Corporate and Commercial Strategies Near-term Focus On Carotid and DES Products, Streamlined Operations BOSTON, MA - January 5, 2015 - InspireMD, Inc.
Read more →NSPRThe MASTER II Trial Comparison of the MGuard Embolic Protection Stent with Standard Stents in Acute Myocardial Infarction Gregg W. Stone, MD Columbia University Medical Center NewYork - Presbyterian Hospital Cardiovascul
The MASTER II Trial Comparison of the MGuard Embolic Protection Stent with Standard Stents in Acute Myocardial Infarction Gregg W. Stone, MD Columbia University Medical Center NewYork - Presbyterian Hospital Cardiovascular Research Foundation Background In the randomized MASTER
Read more →NSPRInspireMD Reports Financial Results
InspireMD Reports Financial Results for the Third Quarter ended September 30, 2014 Master II 30 day data to be presented December 15th at the ICI Meeting 2014, Tel-Aviv Announced first pre-clinical implant with partner DES platform BOSTON, MA - November 12, 2014 - InspireMD
Read more →NSPRInspireMD Completes $8.1 Million Registered Direct Offering BOSTON, MA
InspireMD Completes $8.1 Million Registered BOSTON, MA - November 7, 2014 - InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in stent Embolic Protection Systems (EPS), today announced the closing of its registered direct offering of approximately 6.2 m
Read more →NSPRInspireMD Announces Registered Direct Offering for Approximately $8 Million BOSTON, MA
InspireMD Announces Registered Direct Offering for Approximately $8 Million BOSTON, MA - November 4, 2014 - InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in stent Embolic Protection Systems (EPS), today announced that it has entered into a definiti
Read more →NSPRInspireMD Investigational Device Exemption (IDE) amendment approved by the FDA - - - Validation of manufacturing process changes for the MGuard Prime
InspireMD Investigational Device Exemption (IDE) amendment approved by the FDA manufacturing process changes for the MGuard Prime EPS BOSTON, MA - October 29, 2014 - InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in Embolic Protection Systems (EPS)
Read more →NSPRInspireMD Resumes MGuard Prime Sales and Prioritizes DES and Carotid - New Product Programs - MGuard Prime commercial re-launch complete in direct markets Drug Eluting Stent (DES) program advances in development with par
MGuard Prime Sales and Prioritizes DES and Carotid - New Product Programs commercial re-launch complete in direct markets Stent (DES) program advances in development with partners to suspend enrollment to support DES and Carotid Opportunities call this morning at 8:30 a.m. ET
Read more →NSPRInitial Commercial Sales of the CGuardTM EPS
Initial Commercial Sales of the CGuardTM EPS Commercial activities ahead of schedule following release of strong clinical data in the multi-specialty CARENET trial BOSTON, MA - October 1, 2014 - InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in emb
Read more →NSPRInspireMD to Host Conference Call and Webinar and to Discuss Recently Released Results of CGuard CARENET Trial on September 24 th CARENET Trial data presented at the Transcatheter Cardiovascular Therapeutics (TCT) confer
InspireMD to Host Conference Call and Webinar and to Discuss Recently Released Results of CGuard CARENET Trial on September 24th CARENET Trial data presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference, September 16, 2014, showed 0% MACE at 30 Days Jos
Read more →NSPRJoachim Schofer (PI) Piotr Musialek (Co - PI) On behalf of the CARENET Investigators Evaluation of PET Mesh Covered Stent in Patients with Carotid Artery Disease T he CARENET - Tri
Joachim Schofer (PI) Piotr Musialek (Co - PI) On behalf of the CARENET Investigators Evaluation of PET Mesh Covered Stent in Patients with Carotid Artery Disease T he CARENET - Trial ( CAR otid E mbolic protection using micro NET ) Joachim Schofer, MD,PhD , Hamburg University Car
Read more →NSPRInspireMD to Announce Results of CGuard CARENET Trial at the TCT Innovation Session on Late Breaking Early Human Clinical Studies Results will be announced on Tuesday, September 16 in Washington
InspireMD to Announce Results of CGuard CARENET Trial at the TCT Innovation Session on Late Breaking Early Human Clinical Studies Results will be announced on Tuesday, September 16 in Washington, D.C. BOSTON, MA - August 11, 2014 - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireM
Read more →NSPRInspireMD Reports Financial Results for
InspireMD Reports Financial Results for the Second Quarter Ended June 30, 2014 BOSTON, MA - July 23, 2014 - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection systems ("EPS"), today announced its financial and operating results for
Read more →NSPRInspireMD Appoints Dr.
InspireMD Appoints Dr. James Barry as Chief Operating Officer Strengthens Leadership Team with Addition of Experienced Medical Device Executive BOSTON, MA - July 15, 2014 - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection system
Read more →NSPRInspireMD Announces Successful Completion of CGuard TM CARENET ( CAR otid E mbolic protection study using micro NET ) Trial 100% procedural success rate achieved in first multi-specialty clinical experience
Successful Completion of CGuardTM CARENET (CARotid Embolic protection study using microNET) Trial 100% procedural success rate achieved in first multi-specialty clinical experience BOSTON, MA - July 8, 2014 - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a
Read more →NSPREuropean Regulatory Approval to Resume Manufacturing and Distribution of MGuardTM Prime EPS
European Regulatory Approval to Resume Manufacturing and Distribution of MGuardTM Prime EPS 23, 2014 - InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection systems (EPS), today announced that it received European regulatory approval to
Read more →NSPRInspireMD to Showcase Embolic Systems with MicroNet TM Technology and Results from MASTER I Trial at EuroPCR Conference Company to Present at European Symposium Titled MGuard Embolic Protection Sten
to Showcase Embolic Systems with MicroNetTM Technology and Results from MASTER I Trial at EuroPCR Conference to Present at European Symposium Titled MGuard Embolic Protection Stent: The Importance of Thrombus Management in STEMI Primary PCI 20, 2014 - InspireMD, Inc. ("Inspir
Read more →NSPRVoluntary Field Action for MGuardTM Prime EPS
Voluntary Field Action for MGuardTM Prime EPS 30, 2014 - InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection systems (EPS), today announced that it has initiated a Voluntary Field Action (VFA) following recent reports of MGuard Prime
Read more →NSPRInspireMD Announces First Patient Enrolled Into New CGuard TM CARENET ( CAR otid E mbolic protection study using micro NET ) Clinical Trial Proven Embolic Protection System Expands to Treat Carotid Artery Disease BOSTON,
First Patient Enrolled Into New CGuardTM CARENET (CARotid Embolic protection study using microNET) Protection System Expands to Treat Carotid Artery Disease 19, 2014 - InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection systems, toda
Read more →NSPRThis presentation contains "forward - looking statements .
March 2014 NYSE MKT: NSPR 2 This presentation contains "forward - looking statements . " Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or sim
Read more →NSPRInspireMD Reports Financial Results for the Quarter and Six Month Period Ended
InspireMD Reports Financial Results for the Quarter and Six Month Period Ended December 31, 2013 BOSTON, MA - February 26, 2014 - InspireMD Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection systems, today announced financial and operating r
Read more →NSPRInspireMD to Report Financial Results for Six Month Period Ended
InspireMD to Report Financial Results for Six Month Period Ended December 31, 2013 on Wednesday, February 26, 2014 Ma - February 18, 2014 - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection stents, announced today that it will rele
Read more →NSPRInspireMD Reports Successful Implantation of the New CGuard TM Carotid Embolic System with MicroNet TM Technology Acclaimed Embolic Protection System Expands to Treat Carotid Artery Disease BOSTON, MA
Successful Implantation of the New CGuardTM Carotid Embolic System with MicroNetTM Technology Protection System Expands to Treat Carotid Artery Disease BOSTON, MA - February 5, 2014 - InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protect
Read more →NSPRInspireMD Appoints Rick Olson as Vice President of Global Sales Operations Company Strengthens Leadership Team with Addition of Experienced Global Sales Executive BOSTON, MA
InspireMD Appoints Rick Olson as Vice President of Global Sales Operations Company Strengthens Leadership Team with Addition of Experienced Global Sales Executive BOSTON, MA - December 2, 2013 - InspireMD Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in emb
Read more →NSPREXHBIT 99.1 FOR IMMEDIATE RELEASE InspireMD Reports Financial Results for Quarter Ended
InspireMD Reports Financial Results for Quarter Ended September 30, 2013 BOSTON, MA - November 11, 2013 - InspireMD Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection stents, today announced financial results for the quarter ended September 3
Read more →NSPRNovember 2013 NYSE MKT: NSPR Forward - Looking Statements : This presentation contains "forward - looking statements . " Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticip
November 2013 NYSE MKT: NSPR Forward - Looking Statements : This presentation contains "forward - looking statements . " Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believ
Read more →NSPRMASTER Trial 12 Month Results Prof.
MASTER Trial 12 Month Results Prof. Dariusz Dudek Hospital University of Krakow, Poland on behalf of the MASTER Trial Investigators Disclosure Statement of Financial Interest Grant/Research Support Consulting Fees/Honoraria Major Stock Shareholder/Equity Royalty Income Ownership
Read more →NSPRInspireMD to Ring Opening Bell at New York Stock Exchange on Thursday, October 24th BOSTON, MA
InspireMD to Ring Opening Bell at New on Thursday, October 24th BOSTON, MA - October 23, 2013 - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection stents, announced today that it will ring the Opening Bell at the New York Stock Exc
Read more →NSPRInspireMD Reports Fourth Quarter and Fiscal Year 2013 Results BOSTON, MA
Reports Fourth Quarter and Fiscal Year 2013 Results BOSTON, MA - September 17, 2013 - InspireMD Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection stents, today announced financial results for its fourth quarter and fiscal year ended June 30,
Read more →NSPRSeptember 2013 v50 - 46 NYSE MKT: NSPR Forward - Looking Statements : This presentation contains "forward - looking statements . " Such statements may be preceded by the words "intends," "may," "will," "plans," "expects,
September 2013 v50 - 46 NYSE MKT: NSPR Forward - Looking Statements : This presentation contains "forward - looking statements . " Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims
Read more →NSPRInspireMD to Report Fiscal Year 2013 Results on September 17 th BOSTON, MA
InspireMD to Report Fiscal Year 2013 Results on September 17th BOSTON, MA - September 9, 2013 - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection stents, announced today that it will release its financial results for the fiscal ye
Read more →NSPRInspireMD Announces New Appointment to the Board of Directors BOSTON, MA
InspireMD Announces New Appointment to the Board of Directors BOSTON, MA - September 4, 2013 - InspireMD Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection stents, today announced the appointment of Dr. Campbell Rogers to the Board of Directo
Read more →NSPRInspireMD Announces Participation in Two Investor Conferences in September - - - Presenting at Rodman & Renshaw conference on Tuesday, September 10 th - - - Presenting at Stifel Healthcare conference on Thu
InspireMD Announces Participation in Two Investor Conferences in September Presenting at Rodman & Renshaw conference on Tuesday, September 10th Presenting at Stifel Healthcare conference on Thursday, September 12th BOSTON, MA - August 29, 2013 - InspireMD, Inc. (NYSE MKT:
Read more →NSPRInspireMD Completes First Phase of Manufacturing Upgrade and Partners with HealthLink for Global Logistics and Distribution Services First stage of manufacturing strategy complete with consolidation of Israeli operations
InspireMD Completes First Phase of Manufacturing Upgrade and Partners with HealthLink for Global Logistics and Distribution Services First stage of manufacturing strategy complete with consolidation of Israeli operations Healthlink partnership advances commercial and clinica
Read more →NSPRInspireMD Announces First Patient Enrolled in U.S. Registration Trial for MGuard Prime EPS BOSTON and
InspireMD Announces First Patient Enrolled Registration Trial for MGuard Prime EPS BOSTON and TEL AVIV July 29, 2013 - InspireMD, Inc. (NYSE MKT: NSPR) ("Inspire" or the "Company"), a leader in embolic protection stents, said the first patient has been enrolled in the Master
Read more →NSPRInspireMD to Present at 8 th Annual JMP Healthcare Conference BOSTON and
InspireMD to Present at 8th Annual JMP Healthcare Conference BOSTON and TEL AVIV, Israel, July 3, 2013 /PRNewswire/ -InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection stents, announced that Alan Milinazzo, the Company's President
Read more →NSPRForward - Looking Statements : This presentation contains "forward - looking statements .
Forward - Looking Statements : This presentation contains "forward - looking statements . " Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or s
Read more →NSPRInspireMD to Announce Six-Month Results from the MGuard Embolic Protection Stent (EPS) MASTER Trial at EuroPCR - Strong Conference Presence to Include Presentations/Educational Events Featuring the MGuard Embolic Protect
InspireMD to Announce Six-Month Results from the MGuard Embolic Protection Stent (EPS) MASTER Trial at EuroPCR Presence to Include Presentations/Educational Events Featuring the MGuard Embolic Protection Stent - Host Conference Call on Thursday, May 23rd to Review MASTER Dat
Read more →NSPRMASTER Trial Update & 6 Month Results Prof.
MASTER Trial Update & 6 Month Results Prof. Dr. Sigmund Silber FESC, FACC, FAHA Heart Center at the Isar, Munich, Germany on behalf of the MASTER study group MGUARD : DESIGNED FOR EMBOLIC PROTECTION DESIGN Bare metal stent wrapped with an expandable 20 m MicroNet mesh Polyethyle
Read more →NSPRInspireMD Announces Reimbursement Coverage for MGuard Coronary Embolic Protection Stent (EPS) from Brazil's Largest Private Insurer - More than 18 Million Brazilians have Reimbursable Access to MGuard EPS - BOSTON and TE
InspireMD Announces Reimbursement Coverage for MGuard Coronary Embolic Protection Stent (EPS) from Brazil's Largest Private Insurer - More than 18 Million Brazilians have Reimbursable Access to MGuard EPS - BOSTON and TEL AVIV, MAY 16 - InspireMD, Inc. ("InspireMD" or the "
Read more →NSPRInspireMD Reports Financial Results For Period Ended
InspireMD Reports Financial Results For Period Ended March 31, 2013 33% over prior year - milestones achieved - BOSTON and TEL AVIV, MAY 8, 2013 - InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection stents, today announced financi
Read more →NSPRInspireMD Hires Vice President of Corporate Development Former Covidien Executive, Gwen Bame, Will Focus on Strategic Programs Worldwide TEL AVIV, Israel, APR. 19 - InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MK
InspireMD Hires Vice President of Corporate Development Former Covidien Executive, Gwen Bame, Focus on Strategic Programs Worldwide TEL AVIV, Israel, APR. 19 - InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR) said Gwen K. Bame has joined the Company as Vice P
Read more →NSPRInspireMD Closes $25 Million Underwritten Public Offering TEL AVIV, Israel, APR. 16 - InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR) announced the closing of an underwritten public offering
Closes $25 Million Underwritten Public Offering AVIV, Israel, APR. 16 - InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR) announced the closing of an underwritten public offering of 12.5 million shares of its common stock at a price to the public of $2.00 per sha
Read more →NSPRInspireMD Announces Pricing of Underwritten Public Offering of Common Stock and Listing on NYSE MKT TEL AVIV, Israel, APR 10, 2013 - InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR) announced the pricing o
InspireMD Announces Pricing of Underwritten of Common Stock and Listing on NYSE MKT APR 10, 2013 - InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR) announced the pricing of an underwritten public offering of 12,500,000 shares of its common stock at a price to th
Read more →NSPRInspireMD Receives CE Mark Approval for Carotid Embolic Protection Stent InspireMD's Carotid Embolic Protection Stent, based on InspireMD's proprietary MicroNet TM mesh technology, is designed to provide procedural and p
Receives CE Mark Approval for Carotid Embolic Protection Stent Carotid Embolic Protection Stent, based on InspireMD's proprietary MicroNetTM mesh technology, is designed to provide procedural and post-procedural distal embolic protection in Carotid Artery Stenting (CAS) proced
Read more →NSPRInspireMD Files Amended Registration Statement For Proposed Public Offering Of Common Stock TEL AVIV, Israel, MAR 7, 2013 -- InspireMD, Inc. (OTC: NSPR) (the Company or InspireMD ) filed an amended registra
InspireMD Files Amended Registration For Proposed Public Offering Of Common MAR 7, 2013 -- InspireMD, Inc. (OTC: NSPR) (the "Company" or "InspireMD") filed an amended registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to the resu
Read more →NSPRMichael Berman Joins InspireMD Board Former Boston Scientific Executive and cofounder of numerous successful medical device companies TEL AVIV, Israel, FEB. XX - InspireMD, Inc. ("InspireMD" or the "Company") (OTC: NSPRD
Joins InspireMD Board Scientific Executive and cofounder of numerous successful medical device companies FEB. XX - InspireMD, Inc. ("InspireMD" or the "Company") (OTC: NSPRD) announced that Michael Berman joined its board of directors. Mr. Berman previously served as a Sen
Read more →NSPRInspireMD Reports Results For Period Ended
InspireMD Reports Results For Period Quarter Highlighted by Positive Results at 24th Annual TEL AVIV, Israel, FEB. 4, 2013 - InspireMD, Inc. ("InspireMD" or the "Company") (OTC: NSPRD) announced financial results for the period ended Dec. 31, 2012, the second quarter of its
Read more →NSPRInspireMD Names Alan Milinazzo President and CEO Former Medtronic and Boston Scientific Executive Brings Important Commercial, Operations, International, and Public Company CEO Experience TEL AVIV, Israel - JAN 4 Inspire
Names Alan Milinazzo President and CEO and Boston Scientific Executive Brings Important Commercial, Operations, International, and Public Company CEO Experience - JAN 4 InspireMD, Inc. (OTC: NSPRD) ("InspireMD" or the "Company") appointed Alan W. Milinazzo President, Chief E
Read more →Competitive Position
How NSPR ranks across every disease it competes inCompetitive Position is a premium feature
See how NSPR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial